PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
21707927-10	2011	ANGII or methoxamine given to hexamethonium-pretreated or untreated rats increased MAP similarly, but produced contrasting effects on erectile responses.	Hexamethonium	30-43	angiotensinogen	Rattus norvegicus	0-5
21112947-9	2011	When animals from all studies underwent ganglionic blockade with hexamethonium, there was a smaller reduction in the fall of BP in animals receiving icv AT1R or MR antagonists.	Hexamethonium	65-78	angiotensin II receptor, type 1a	Rattus norvegicus	153-157
21112947-9	2011	When animals from all studies underwent ganglionic blockade with hexamethonium, there was a smaller reduction in the fall of BP in animals receiving icv AT1R or MR antagonists.	Hexamethonium	65-78	nuclear receptor subfamily 3, group C, member 2	Rattus norvegicus	161-163
21073474-5	2011	UVA irradiation of the eye suppressed the intestinal peristalsis of control, hypophysectomized or iNOS(-/-) C57BL/6J mice by the mechanism that was inhibited by hexamethonium or prazosin plus propranolol.	Hexamethonium	161-174	nitric oxide synthase 2, inducible	Mus musculus	98-102
20679729-8	2010	By contrast, inhibition of ganglionic transmission with either hexamethonium or prazosin abolished the difference in blood pressure between Trpm4-/- and wild-type mice.	Hexamethonium	63-76	transient receptor potential cation channel, subfamily M, member 4	Mus musculus	140-145
20615399-7	2010	In sigmoid circular muscle, neurotensin responses were also enhanced by TTX and hexamethonium, but were attenuated in the presence of mepyramine, MEN10627 and CP99994, suggesting inhibitory neuronal mechanisms and involvement of histamine and tachykinins, respectively; L-NAME and the GABA(B) receptor antagonist, CGP36742, were without effect.	Hexamethonium	80-93	neurotensin	Homo sapiens	28-39
20602018-6	2010	However, hexamethonium + ouabain increased DAP sensitivity to PHE.	Hexamethonium	9-22	death-associated protein	Rattus norvegicus	43-46
18651290-14	2008	Hexamethonium, a nonselective antagonist of nicotinic acetylcholine receptors (nAChRs), significantly inhibited nicotine-induced VEGF protein expression (P < 0.01).	Hexamethonium	0-13	vascular endothelial growth factor A	Oryctolagus cuniculus	129-133
19914944-12	2010	The marked rise in heart rate in response to UCN2 is preserved in sheep undergoing pharmacological ganglionic blockade with hexamethonium.	Hexamethonium	124-137	urocortin-2	Ovis aries	45-49
19749751-6	2009	In the presence of the general nAChR blocker hexamethonium, nociceptive neurons showed nicotine-induced responses that were strongly reduced in TRPA1-deficient mice.	Hexamethonium	45-58	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	31-36
19749751-6	2009	In the presence of the general nAChR blocker hexamethonium, nociceptive neurons showed nicotine-induced responses that were strongly reduced in TRPA1-deficient mice.	Hexamethonium	45-58	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	144-149
20105082-3	2010	Dihydrobetaerythroidine (antagonist of heteromeric nAChR), and hexamethonium (antagonist of peripheral nAChR), fully antagonized the effect of MDMA.	Hexamethonium	63-76	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	103-108
19239625-7	2009	Pretreatment with hexamethonium markedly reduced gastric relaxation induced by secretin (5.6 pmol kg(-1) h(-1)).	Hexamethonium	18-31	secretin	Rattus norvegicus	79-87
19070647-6	2009	When coapplied with 100microM ACh, HBB concentration-dependently suppressed currents with an IC(50) value of 0.19+/-0.04microM, and was approximately seven-times more potent than the ganglionic blocker, hexamethonium (IC(50)=1.3+/-0.3microM).	Hexamethonium	203-216	hemoglobin subunit beta	Homo sapiens	35-38
18162319-10	2008	600 micromol/kg of CDP-choline, phosphocholine or choline were abolished by pretreatment with the ganglionic nicotinic acetylcholine receptor antagonist hexamethonium (15 mg/kg; i.p.	Hexamethonium	153-166	cut-like homeobox 1	Rattus norvegicus	19-22
18567834-6	2008	The subunit-nonselective nAChR antagonist hexamethonium (100 micromol/kg) and the selective alpha7-subunit antagonist methyllycaconitine (MLA; 3 and 10 micromol/kg) decreased the nicotine-induced tachycardia by 100 and 40%, respectively (maximal effects), suggesting that nAChRs containing the alpha7-subunit account for 40% of the nicotine-induced tachycardia.	Hexamethonium	42-55	cholinergic receptor nicotinic beta 1 subunit	Rattus norvegicus	25-30
18499160-9	2008	RESULTS: Intravesical lidocaine or ganglionic blockage with hexamethonium prevented substance P induced macrophage migration inhibitory factor release.	Hexamethonium	60-73	macrophage migration inhibitory factor	Rattus norvegicus	104-142
18258664-6	2008	The KCl-induced increase in TH expression was partly reduced in the presence of the nicotinic receptor antagonist hexamethonium (100 microm), of noradrenaline (1 microm) and of the alpha(2)-adrenoreceptor agonist clonidine (1 microm).	Hexamethonium	114-127	tyrosine hydroxylase	Rattus norvegicus	28-30
18079280-9	2008	FTS Ca(2+) responses were inhibited by Omega-conotoxin (70%), hexamethonium (50%), TTX, high Mg(2+)/low Ca(2+) (< or = 100%), or capsaicin (25%).	Hexamethonium	62-75	AKT interacting protein	Homo sapiens	0-3
18423439-4	2008	In addition, the corticotropin-releasing factor-induced elevation of noradrenaline release in the hypothalamic paraventricular nucleus and plasma corticosterone were abolished by hexamethonium, a non-selective nicotinic acetylcholine receptor antagonist, at 1.8 micromol/animal, intracerebroventricularly, and alpha-conotoxin MII, a potent alpha(3)beta(2) nicotinic acetylcholine receptor antagonist, at 30 nmol/animal, i.c.v.	Hexamethonium	179-192	corticotropin releasing hormone	Rattus norvegicus	17-47
18423439-4	2008	In addition, the corticotropin-releasing factor-induced elevation of noradrenaline release in the hypothalamic paraventricular nucleus and plasma corticosterone were abolished by hexamethonium, a non-selective nicotinic acetylcholine receptor antagonist, at 1.8 micromol/animal, intracerebroventricularly, and alpha-conotoxin MII, a potent alpha(3)beta(2) nicotinic acetylcholine receptor antagonist, at 30 nmol/animal, i.c.v.	Hexamethonium	179-192	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	210-242
18423439-4	2008	In addition, the corticotropin-releasing factor-induced elevation of noradrenaline release in the hypothalamic paraventricular nucleus and plasma corticosterone were abolished by hexamethonium, a non-selective nicotinic acetylcholine receptor antagonist, at 1.8 micromol/animal, intracerebroventricularly, and alpha-conotoxin MII, a potent alpha(3)beta(2) nicotinic acetylcholine receptor antagonist, at 30 nmol/animal, i.c.v.	Hexamethonium	179-192	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	356-388
17727820-4	2007	The classical antagonists, hexamethonium and decamethonium, differentiate between peripheral nAChR subtypes.	Hexamethonium	27-40	cholinergic receptor nicotinic beta 1 subunit	Rattus norvegicus	93-98
18257750-9	2008	600 mumol/kg of CDP-choline, phosphocholine or choline were abolished by pre-treatment with hexamethonium (15 mg/kg; i.p.	Hexamethonium	92-105	cut like homeobox 1	Homo sapiens	16-19
17884041-6	2007	Pretreatment with atropine plus hexamethonium attenuated or blocked pressor response to CDP-choline or phosphocholine, respectively.	Hexamethonium	32-45	cut-like homeobox 1	Rattus norvegicus	88-91
17884041-7	2007	Heart rate responses to CDP-choline, phosphocholine and choline were blocked by atropine and reversed by hexamethonium.	Hexamethonium	105-118	cut-like homeobox 1	Rattus norvegicus	24-27
17900562-6	2007	Truncal vagotomy, perivagal application of capsaicin and hexamethonium reduced CNP-evoked pancreatic flow and abolished chloride excretion but did not affect protein output.	Hexamethonium	57-70	natriuretic peptide C	Rattus norvegicus	79-82
17666046-5	2007	Nicotine-induced ERK phosphorylation was inhibited by high concentrations of mecamylamine, however it was not blocked by other broad nicotinic acetylcholine receptor (nAChR) inhibitors (including hexamethonium and chlorisondamine) or nAChR subtype selective inhibitors (such as methyllycaconitine, alpha-bungarotoxin, dihydro-beta-erythroidine, and alpha-conotoxin Au1B).	Hexamethonium	196-209	mitogen-activated protein kinase 1	Mus musculus	17-20
17517423-4	2007	Cis-4-aminocrotonic acid (CACA), a specific GABA(C) receptor agonist, induced an inhibitory effect, consisting in the reduction of the amplitude of the spontaneous contractions and muscular relaxation, which was antagonised by TPMPA, GABA(C)-receptor antagonist, TTX or N(omega)-nitro-l-arginine methyl ester (L-NAME), nitric oxide (NO) synthase inhibitor, but not affected by hexamethonium.	Hexamethonium	377-390	suppressor of cytokine signaling 6	Mus musculus	0-5
17784838-6	2007	Furthermore, the antiapoptotic effect of nicotine was blocked completely by nicotinic acetylcholine receptor (nAChR) antagonist hexamethonium.	Hexamethonium	128-141	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	76-108
17784838-6	2007	Furthermore, the antiapoptotic effect of nicotine was blocked completely by nicotinic acetylcholine receptor (nAChR) antagonist hexamethonium.	Hexamethonium	128-141	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	110-115
17517423-4	2007	Cis-4-aminocrotonic acid (CACA), a specific GABA(C) receptor agonist, induced an inhibitory effect, consisting in the reduction of the amplitude of the spontaneous contractions and muscular relaxation, which was antagonised by TPMPA, GABA(C)-receptor antagonist, TTX or N(omega)-nitro-l-arginine methyl ester (L-NAME), nitric oxide (NO) synthase inhibitor, but not affected by hexamethonium.	Hexamethonium	377-390	gamma-aminobutyric acid (GABA) C receptor, subunit rho 2	Mus musculus	234-250
17286987-5	2007	Hexamethonium, an antagonist of nicotinic acetylcholine receptor (nAChR), inhibited nicotine-induced VEGF release.	Hexamethonium	0-13	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	32-64
17286987-5	2007	Hexamethonium, an antagonist of nicotinic acetylcholine receptor (nAChR), inhibited nicotine-induced VEGF release.	Hexamethonium	0-13	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	66-71
17286987-5	2007	Hexamethonium, an antagonist of nicotinic acetylcholine receptor (nAChR), inhibited nicotine-induced VEGF release.	Hexamethonium	0-13	vascular endothelial growth factor A	Rattus norvegicus	101-105
17334538-3	2007	Sympathetic blockade with hexamethonium essentially caused a decrease in total peripheral resistance in hypertensive animals (conscious, 2 days: from (means +/- SEM) 2.47 +/- 0.08 to 2.14 +/- 0.07; conscious, 7 days: from 2.85 +/- 0.13 to 2.07 +/- 0.33; anesthetized, 2 days: from 3.00 +/- 0.09 to 1.83 +/- 0.25 and anesthetized, 7 days: from 3.56 +/- 0.11 to 1.53 +/- 0.10 mmHg mL-1 min-1) with no change in CO in either group.	Hexamethonium	26-39	L1 cell adhesion molecule	Mus musculus	379-389
16762378-7	2006	The OXA-induced contraction was significantly inhibited by hexamethonium and SB-334867-A, whereas the nicotine-induced contraction was not inhibited by SB-334867-A.	Hexamethonium	59-72	hypocretin	Mus musculus	4-7
16938493-10	2007	Icv-injection of GLP-1 (3 nmol)-induced acceleration of colonic transit was attenuated by vagotomy, atropine and hexamethonium, but not by guanethidine.	Hexamethonium	113-126	glucagon	Rattus norvegicus	17-22
17141214-8	2007	The present results suggest that subchronic treatment with the nicotinic acetylcholine receptor antagonist hexamethonium reduces a GABA(A)-R mediated counteraction of the nucleus accumbens dopamine response to ethanol.	Hexamethonium	107-120	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	63-95
17085676-9	2007	However, hexamethonium after previous antagonism of the angiotensin II type 1 (AT(1)) receptors with losartan produced a larger decrease in MAP in the CIH than in the control group (-58 +/- 2 versus -50 +/- 2 mmHg, P = 0.0165).	Hexamethonium	9-22	angiotensin II receptor, type 1a	Rattus norvegicus	56-84
15576667-6	2005	Prazosin and hexamethonium produced greater decreases in mean AP in AT1a -/- than in AT1a +/+.	Hexamethonium	13-26	angiotensin II receptor, type 1a	Mus musculus	68-72
16469825-4	2006	Pretreatment with atropine or hexamethonium or an acute vagotomy, but not a perivagal application of capsaicin, completely abolished pancreatic protein secretion responses to ghrelin.	Hexamethonium	30-43	ghrelin and obestatin prepropeptide	Rattus norvegicus	175-182
16520739-3	2006	Stimulation of PAR-2 by trypsin-induced relaxation of carbachol- and KCl-induced contractions in normal rat colonic smooth muscle was completely resolved by tissue pretreatment with apamin, but not by pretreatment with l-NMMA or a cocktail of neuronal blockers (tetrodotoxin, hexamethonium and propranolol).	Hexamethonium	276-289	F2R like trypsin receptor 1	Rattus norvegicus	15-20
15680490-9	2005	Ganglion blockade with hexamethonium did not influence CGRP release by RPC but abolished CGRP mediated myocardial PKCepsilon activation.	Hexamethonium	23-36	calcitonin-related polypeptide alpha	Rattus norvegicus	89-93
16762503-8	2006	Both the plasma glucose lowering action and the raised plasma levels of insulin and C-peptide induced by Hon-Chi were also inhibited by 4-diphenylacetoxy-N-methylpiperdine methiodide (4-DAMP), but not affected by the ganglionic nicotinic antagonist, pentolinium or hexamethonium, indicating the mediation of muscarinic M(3) receptors.	Hexamethonium	265-278	insulin 2	Rattus norvegicus	84-93
16792571-10	2006	Intracerebellar pretreatment with hexamethonium, a nicotinic receptor (nAChR) antagonist, significantly blocked nicotine-induced attenuation of ethanol ataxia suggesting participation of nAChRs.	Hexamethonium	34-47	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	71-76
16263110-5	2005	CNP response was diminished by atropine and hexamethonium, but it was abolished by vagotomy.	Hexamethonium	44-57	natriuretic peptide C	Rattus norvegicus	0-3
15576667-6	2005	Prazosin and hexamethonium produced greater decreases in mean AP in AT1a -/- than in AT1a +/+.	Hexamethonium	13-26	angiotensin II receptor, type 1a	Mus musculus	85-89
14714611-3	2003	The insulin-releasing activity of motilin in the fed state was completely abolished by pretreatment with atropine or hexamethonium and was partly inhibited by ondansetron.	Hexamethonium	117-130	insulin	Canis lupus familiaris	4-11
15501701-8	2004	The excitatory response to vasopressin was Tetrodotoxin [TTX]-resistant and was not affected by pre-treatment with phentolamine [10(-5) M], atropine [10(-5) M], and hexamethonium [10(-5) M].	Hexamethonium	165-178	arginine vasopressin	Homo sapiens	27-38
15066018-6	2004	Pretreatment with capsaicin or hexamethonium, combination of both pretreatments or vagotomy reduced HCl-induced c-Fos expression by 54%, 66%, 63% and 68%, respectively.	Hexamethonium	31-44	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	112-117
15707012-6	2004	infusion of orphanin FQ (36 microg) also prevented the onset of aconitine-induced arrhythmia, but this effect was completely abolished by hexamethonium.	Hexamethonium	138-151	prepronociceptin	Rattus norvegicus	12-23
15273750-2	2004	Atropine reduced, while hexamethonium completely abolished the arrhythmogenic effect of endothelin-1 during nitric oxide synthase inhibition.	Hexamethonium	24-37	endothelin 1	Mus musculus	88-100
14714611-3	2003	The insulin-releasing activity of motilin in the fed state was completely abolished by pretreatment with atropine or hexamethonium and was partly inhibited by ondansetron.	Hexamethonium	117-130	motilin	Canis lupus familiaris	34-41
15040854-11	2003	Pretreatment with the ganglion blocker hexamethonium and with atropine completely abolished the stimulatory effect of central ghrelin.	Hexamethonium	39-52	ghrelin and obestatin prepropeptide	Rattus norvegicus	126-133
14573394-5	2003	Like nicotine, the contraction induced by 100 nM urotensin II was inhibited by treatment with atropine, hexamethonium, D-tubocurarine, tetrodotoxin or hemicholinium-3, and enhanced by physostigmine.	Hexamethonium	104-117	urotensin 2	Homo sapiens	49-61
12829438-12	2003	Moreover, in the presence of hexamethonium or Nomega-nitro-l-arginine methyl ester, an inhibitor of NOS, responses caused by mGluR8 agonists were abolished.	Hexamethonium	29-42	glutamate receptor, metabotropic 8	Mus musculus	125-131
12740863-4	2003	The rank potency order of nAChR antagonists to reduce tetanic peak tension was alpha-bungarotoxin > d-tubocurarine >> mecamylamine > hexamethonium.	Hexamethonium	145-158	cholinergic receptor nicotinic beta 1 subunit	Rattus norvegicus	26-31
12898092-4	2003	The nicotinic antagonists HXM (50 microM), methyllycaconitine (MLA, 0.01 microM) and dihydro-beta-erythroidine (DHbetaE, 50 microM) potentiated CA3-evoked field potentials.	Hexamethonium	26-29	carbonic anhydrase 3	Rattus norvegicus	144-147
12966717-3	2003	Intracerebroventricular infusion of orphanin FQ was shown to increase cardiac tolerance of arrhythmogenic influence of aconitine, but this effect is completely abolished by hexamethonium administration.	Hexamethonium	173-186	prepronociceptin	Homo sapiens	36-47
12711315-8	2003	Plasma ghrelin levels in hexamethonium-treated animals were greater (P<0.05) than those of atropine-treated animals.	Hexamethonium	25-38	appetite-regulating hormone	Ovis aries	7-14
12606764-4	2003	beta 4(-/-) mice had an attenuated bradycardiac response to high frequency (60 pulse/s) vagal stimulation, as well as an increased sensitivity to hexamethonium blockade at low dose (3 mg/kg) and a reduced ileal contractile response to the nicotinic agonists cytisine, dimethylphenylpiperazinium iodide, nicotine (10 mg/kg each), and epibatidine (0.1 mg/kg).	Hexamethonium	146-159	basic helix-loop-helix family, member e23	Mus musculus	0-6
12595959-0	2003	Inhibitory effects of atropine and hexamethonium on the angiotensin II-induced contractions of rat anococcygeus smooth muscles.	Hexamethonium	35-48	angiotensinogen	Rattus norvegicus	56-70
12595959-6	2003	Additionally, hexamethonium inhibited the contraction induced by Ang II in a concentration-dependent fashion with a decrease in E(max).	Hexamethonium	14-27	angiotensinogen	Rattus norvegicus	65-71
12588467-6	2003	Pre-treatment with capsaicin or hexamethonium or a combination of both pre-treatments reduced HCl-induced c-Fos expression by 54, 66 and 63%, respectively.	Hexamethonium	32-45	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	106-111
12595959-7	2003	Association of atropine and hexamethonium produced Ang II-induced curves with rightward shifts from the control curve with a decrease in E(max).	Hexamethonium	28-41	angiotensinogen	Rattus norvegicus	51-57
12488235-3	2003	The nicotinic agonist 1,1-dimethyl-4-phenylpiperazinium (DMPP) stimulated ANP secretion; the effect was abolished by hexamethonium but doubled by atropine.	Hexamethonium	117-130	natriuretic peptide A	Rattus norvegicus	74-77
28095236-8	2001	Pressor responses to Ang II were not altered by propranolol, phentolamine or atropine, but were enhanced by hexamethonium.	Hexamethonium	108-121	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	21-27
11413111-8	2001	Pretreatment with hexamethonium (low toxin concentration; acute denervation) attenuated the effect of toxin A on morphology, luminal MPO activity, and number of RBCs.	Hexamethonium	18-31	myeloperoxidase	Rattus norvegicus	133-136
11292608-4	2001	Hexamethonium (20 mg/kg sc) prevented Fos expression by 90%, whereas atropine (2 mg/kg sc) had no effect.	Hexamethonium	0-13	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	38-41
12522097-7	2003	4 The nicotinic ganglionic acetylcholine receptor antagonist hexamethonium (1 microM) and the muscarinic acetylcholine receptor antagonist atropine (1 microM) also decreased the NK(3) receptor agonist-induced J(G) by 67% (n=10) and 71% (n=12), respectively.	Hexamethonium	61-74	tachykinin receptor 3	Homo sapiens	178-192
12508375-6	2003	Hexamethonium (10 micromol x L(-1)) partly blocked the inhibition of oxytocin (1 U x L(-1)) on the contractile frenquency of CM.	Hexamethonium	0-13	oxytocin	Oryctolagus cuniculus	69-77
12409836-8	2002	Pretreatment with the ganglion blocker hexamethonium and with atropine completely abolished the stimulatory effect of central Orexin-A.	Hexamethonium	39-52	hypocretin neuropeptide precursor	Rattus norvegicus	126-134
12047040-6	2002	Successive administration of V1A after ganglionic blockade with hexamethonium bromide (C6; 25 mg/kg), however, significantly attenuated renal, mesenteric and hindquarter resistances in BHR but not in NCR.	Hexamethonium	64-85	arginine vasopressin receptor 1A	Rattus norvegicus	29-32
11447037-4	2001	Hexamethonium (20 mg/kg) also prevented 3-h cold exposure-induced myenteric Fos expression by 76-80%, whereas atropine or bretylium had no effect.	Hexamethonium	0-13	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	76-79
11223191-6	2001	Hexamethonium decreased by 50% the post BNx increase in prorenin but not active renin.	Hexamethonium	0-13	renin	Rattus norvegicus	59-64
10702597-0	2000	Intravenous infusion of hexamethonium and atropine but not propranolol diminishes apolipoprotein A-IV gene expression in rat ileum.	Hexamethonium	24-37	apolipoprotein A4	Rattus norvegicus	82-101
11731102-3	2001	In contrast, EPSPs were abolished by the nicotinic acetylcholine receptor antagonists, hexamethonium and mecamylamine.	Hexamethonium	87-100	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	41-73
11123707-9	2000	Motilin release in response to PGE2 was significantly increased by pretreatment with hexamethonium.	Hexamethonium	85-98	motilin	Canis lupus familiaris	0-7
11038246-2	2000	Nicotine-induced (0.1 microM) increases in DBI mRNA expression were abolished by hexamethonium, a nicotinic acetylcholine (nACh) receptor antagonist.	Hexamethonium	81-94	diazepam binding inhibitor	Mus musculus	43-46
10974664-4	2000	The VIP/PACAP-elicited secretion was diminished in the presence of the VIP receptor antagonist, VIP 6-28, but was unaffected by the PACAP receptor antagonist, PACAP 6-27, or the cholinergic antagonists, hexamethonium and atropine.	Hexamethonium	203-216	vasoactive intestinal peptide	Gallus gallus	4-7
10898747-4	2000	The PAF-induced contractions were not significantly reduced by TTX, atropine, or hexamethonium but were significantly inhibited with the PAF receptor antagonists ginkolide B and CV-3988.	Hexamethonium	81-94	PCNA clamp associated factor	Homo sapiens	4-7
10854732-5	2000	These effects were diminished by prior administration of hexamethonium (nACh-R blocker) within the commissural subnucleus of the nTS.	Hexamethonium	57-70	neurotensin/neuromedin N	Mustela putorius furo	129-132
10811733-3	2000	The P2X purinoceptor blocker, suramin (50 microM) or a nicotinic ACh receptor (nAChR) blocker (hexamethonium, 100 microM; mecamylamine, 1 microM) only partially inhibited these responses, but together, blocked almost all activity.	Hexamethonium	95-108	cholinergic receptor nicotinic beta 1 subunit	Rattus norvegicus	79-84
10702597-3	2000	Apo A-IV mRNA levels in the ileum were significantly lower in hexamethonium- or atropine-infused rats than in saline- (control) or propranolol-infused rats.	Hexamethonium	62-75	apolipoprotein A4	Rattus norvegicus	0-8
10702597-5	2000	The lower mRNA levels of apo A-IV in the ileum of hexamethonium-infused rats were observed even in bile-drained rats, indicating that the lower expression was not due to any changes in bile availability.	Hexamethonium	50-63	apolipoprotein A4	Rattus norvegicus	25-33
10704720-4	2000	The effect of peptide YY was blocked or strongly decreased by tetrodotoxin, hexamethonium, idazoxan, haloperidol, and the sigma antagonist BMY 14, 802 in both the colon and jejunum.	Hexamethonium	76-89	peptide YY	Rattus norvegicus	14-24
10409218-4	1999	Atropine and hexamethonium partially decreased c-fos expression (banding vs. banding + atropine/hexamethonium: 700 +/- 67% vs. 400 +/- 67%, P < 0.05).	Hexamethonium	13-26	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	47-52
10592302-3	1999	Intraperitoneal administration of the ganglion blocker hexamethonium (20 mg/kg) or the beta-adrenergic antagonist propranolol (5 mg/kg) suppressed the CGRP-induced increases in VO(2), HR, T(co), and T(IBAT).	Hexamethonium	55-68	calcitonin-related polypeptide alpha	Rattus norvegicus	151-155
10592302-3	1999	Intraperitoneal administration of the ganglion blocker hexamethonium (20 mg/kg) or the beta-adrenergic antagonist propranolol (5 mg/kg) suppressed the CGRP-induced increases in VO(2), HR, T(co), and T(IBAT).	Hexamethonium	55-68	solute carrier family 10 member 2	Rattus norvegicus	201-205
10444454-7	1999	CRH-induced changes in ion secretion were abolished by alpha-helical CRH-(9-41), hexamethonium, atropine, or doxantrazole.	Hexamethonium	81-94	corticotropin releasing hormone	Rattus norvegicus	0-3
10444454-8	1999	CRH-stimulated conductance was significantly inhibited by alpha-helical CRH-(9-41), hexamethonium, bretylium, or doxantrazole.	Hexamethonium	84-97	corticotropin releasing hormone	Rattus norvegicus	0-3
10409218-4	1999	Atropine and hexamethonium partially decreased c-fos expression (banding vs. banding + atropine/hexamethonium: 700 +/- 67% vs. 400 +/- 67%, P < 0.05).	Hexamethonium	96-109	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	47-52
10386968-5	1999	Also absent was an effect by DMPP on the rate of degradation of TH protein because pulse-chase analysis estimated a half-life for TH of 26 +/- 5 h in DMPP-treated cells, a value that was (a) essentially the same as that estimated in control cells (29 +/- 3 h), (b) within the same range as that estimated by approach to steady state (t(1/2) = 19 +/- 4 h), which measured the decline of TH protein content from the DMPP-induced steady-state level back to the basal value during deinduction with the nicotinic antagonist hexamethonium, and (c) consistent with the time course of accumulation of TH protein to a new steady-state level in response to DMPP.	Hexamethonium	519-532	tyrosine hydroxylase	Bos taurus	64-66
9915830-10	1999	Peptide nicotinic antagonists (catestatins, substance P) were far more potent inhibitors of both secretion (p = 0.019) and desensitization (p = 0.005) than nonpeptide antagonists (trimethaphan, hexamethonium, procaine, phencyclidine, cocaine, or clonidine), and the peptides displayed enhanced selectivity to block desensitization versus secretion (p = 0.003).	Hexamethonium	194-207	tachykinin precursor 1	Homo sapiens	44-55
10363713-11	1999	Distension elicited hexamethonium-resistant pCREB immunoreactivity in calbindin-immunoreactive neurons in each plexus; however, in preparations stimulated in the presence of omega-CTx GVIA, pCREB immunoreactivity was found only in calbindin-immunoreactive neurons in the submucosal plexus and not in myenteric ganglia.	Hexamethonium	20-33	calbindin 1	Rattus norvegicus	70-79
10363713-11	1999	Distension elicited hexamethonium-resistant pCREB immunoreactivity in calbindin-immunoreactive neurons in each plexus; however, in preparations stimulated in the presence of omega-CTx GVIA, pCREB immunoreactivity was found only in calbindin-immunoreactive neurons in the submucosal plexus and not in myenteric ganglia.	Hexamethonium	20-33	calbindin 1	Rattus norvegicus	231-240
9568379-0	1998	Effects of hexamethonium, phenothiazines, propranolol and ephedrine on acetylcholinesterase carbamylation by physostigmine, aldicarb and carbaryl: interaction between the active site and the functionally distinct peripheral sites in acetylcholinesterase.	Hexamethonium	11-24	acetylcholinesterase (Cartwright blood group)	Homo sapiens	71-91
9869543-13	1998	ET-1 in the hexamethonium group (n = 2) rose from 2.21 +/- .14 to 11.5 +/- 2.1 pg/ml at 2 hours, and in the spinal group (n = 7) from 2.04 +/- 0.77 to 6.85 +/- 3.9 pg/mL at 45 minutes.	Hexamethonium	12-25	endothelin-1	Sus scrofa	0-4
9756504-7	1998	A single injection of TTX, atropine, or hexamethonium reduced the luminal release of 5-HT, whereas a single injection of VIP-(10-28) stimulated the luminal release of 5-HT and this effect was antagonized by atropine, hexamethonium, or TTX.	Hexamethonium	217-230	vasoactive intestinal peptide	Rattus norvegicus	121-124
9657354-8	1998	Moreover, inhibition of gastrointestinal motor activity by GLP-1 was blocked by previous infusion of hexamethonium (10 mg/kg) (n = 4).	Hexamethonium	101-114	glucagon	Rattus norvegicus	59-64
9495824-1	1998	To extend our knowledge of the pharmacological profile of human alpha4beta2 neuronal nicotinic receptors, we investigated the action of hexamethonium on the major brain human nicotinic acetylcholine receptor (nAChR) stably expressed in human embryonic kidney 293 cells.	Hexamethonium	136-149	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	175-207
9495824-1	1998	To extend our knowledge of the pharmacological profile of human alpha4beta2 neuronal nicotinic receptors, we investigated the action of hexamethonium on the major brain human nicotinic acetylcholine receptor (nAChR) stably expressed in human embryonic kidney 293 cells.	Hexamethonium	136-149	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	209-214
9526051-5	1998	Furthermore, this pressor effect of parathyroid hormone-related protein was also abolished after pretreatment by intravenous administration of either hexamethonium bromide or doxazosin mesylate.	Hexamethonium	150-171	parathyroid hormone-like hormone	Rattus norvegicus	36-71
9458777-5	1998	Exogenous motilin (0.01-0.3 microgram/kg) dose dependently stimulated insulin release, which was abolished by atropine, hexamethonium, ondansetron, and truncal vagotomy.	Hexamethonium	120-133	insulin	Canis lupus familiaris	70-77
9568379-8	1998	Ephedrine, propranolol and phenothiazines including trifluoparazine (TPZ) caused non-competitive inhibition, while hexamethonium caused an uncompetitive inhibition of AChE activity.	Hexamethonium	115-128	acetylcholinesterase (Cartwright blood group)	Homo sapiens	167-171
9568379-12	1998	Hexamethonium protected AChE from inhibition by carbamates and decreased the fluorescence intensity of the physostigmine-inhibited AChE.	Hexamethonium	0-13	acetylcholinesterase (Cartwright blood group)	Homo sapiens	24-28
9568379-12	1998	Hexamethonium protected AChE from inhibition by carbamates and decreased the fluorescence intensity of the physostigmine-inhibited AChE.	Hexamethonium	0-13	acetylcholinesterase (Cartwright blood group)	Homo sapiens	131-135
9044380-7	1997	The nicotinic acetylcholine receptor antagonists (n-bungarotoxin > mecamylamine > (+)-tubocurarine > hexamethonium > alpha-bungarotoxin = dihydro-beta-erythroidine) and tetrodotoxin antagonized the effect of dimethylphenylpiperazinium to release [3H]noradrenaline.	Hexamethonium	110-123	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	4-36
9335407-5	1997	The pressor and bradycardic effects evoked by microinjection of ET-1 into the NTS could be blocked by local pretreatment with PD147953 and completely eliminated by intravenous pretreatment with the ganglionic blocker hexamethonium.	Hexamethonium	217-230	endothelin 1	Rattus norvegicus	64-68
9350974-9	1997	Pancreatic VIP release during VNS was not affected by atropine, whereas ganglionic blockade with hexamethonium nearly abolished the VIP response to VNS (p<0.005 vs control), suggesting that VIP is a postganglionic neurotransmitter in the dog pancreas.	Hexamethonium	97-110	vasoactive intestinal peptide	Canis lupus familiaris	132-135
9350974-9	1997	Pancreatic VIP release during VNS was not affected by atropine, whereas ganglionic blockade with hexamethonium nearly abolished the VIP response to VNS (p<0.005 vs control), suggesting that VIP is a postganglionic neurotransmitter in the dog pancreas.	Hexamethonium	97-110	vasoactive intestinal peptide	Canis lupus familiaris	132-135
9359598-5	1997	- 60 mV), ACh induced a hexamethonium-sensitive, inward current (IACh), mimicked by nicotine application, suggesting the presence of neuronal nicotinic acetylcholine receptors (nAChR).	Hexamethonium	24-37	cholinergic receptor nicotinic beta 1 subunit	Rattus norvegicus	142-175
9359598-5	1997	- 60 mV), ACh induced a hexamethonium-sensitive, inward current (IACh), mimicked by nicotine application, suggesting the presence of neuronal nicotinic acetylcholine receptors (nAChR).	Hexamethonium	24-37	cholinergic receptor nicotinic beta 1 subunit	Rattus norvegicus	177-182
9277431-4	1997	Distension-induced Fos expression was blocked by omega-conotoxin and significantly reduced by hexamethonium, indicating that neurons expressing Fos immunoreactivity were activated synaptically.	Hexamethonium	94-107	proto-oncogene c-Fos	Cavia porcellus	19-22
9277431-4	1997	Distension-induced Fos expression was blocked by omega-conotoxin and significantly reduced by hexamethonium, indicating that neurons expressing Fos immunoreactivity were activated synaptically.	Hexamethonium	94-107	proto-oncogene c-Fos	Cavia porcellus	144-147
9277467-5	1997	In contrast, administration of the nicotinic receptor blocker hexamethonium bromide abolished both the depressor and the bradycardic responses elicited by stimulation of the hDB.	Hexamethonium	62-83	integrator complex subunit 6	Homo sapiens	174-177
9299636-6	1997	Atropine or hexamethonium significantly inhibited L-NNA-induced phase III-like contractions and the increase in motilin level.	Hexamethonium	12-25	motilin	Canis lupus familiaris	112-119
9299636-7	1997	Atropine or hexamethonium significantly inhibited L-NNA-induced phase III-like contractions and the increase in motilin level.	Hexamethonium	12-25	motilin	Canis lupus familiaris	112-119
9583573-10	1998	The ganglionic blocking agent, hexamethonium, which blocks autonomic but not afferent pathways to the LUT, decreased c-fos expression by 50%.	Hexamethonium	31-44	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	117-122
9502051-0	1997	Evaluation of the nature of camel retinal acetylcholinesterase: inhibition by hexamethonium.	Hexamethonium	78-91	acetylcholinesterase	Camelus bactrianus	42-62
9502051-1	1997	Acetylcholinesterase (AChE, EC 3.1.1.7) has been demonstrated in retinas of several species, however, the nature of the interaction of AChE with specific inhibitors are very limited in the literature and the mode of inhibition of camel retinal AChE by hexamethonium has been studied.	Hexamethonium	252-265	acetylcholinesterase	Camelus bactrianus	0-20
9502051-1	1997	Acetylcholinesterase (AChE, EC 3.1.1.7) has been demonstrated in retinas of several species, however, the nature of the interaction of AChE with specific inhibitors are very limited in the literature and the mode of inhibition of camel retinal AChE by hexamethonium has been studied.	Hexamethonium	252-265	acetylcholinesterase	Camelus bactrianus	22-26
9502051-1	1997	Acetylcholinesterase (AChE, EC 3.1.1.7) has been demonstrated in retinas of several species, however, the nature of the interaction of AChE with specific inhibitors are very limited in the literature and the mode of inhibition of camel retinal AChE by hexamethonium has been studied.	Hexamethonium	252-265	acetylcholinesterase	Camelus bactrianus	135-139
9502051-1	1997	Acetylcholinesterase (AChE, EC 3.1.1.7) has been demonstrated in retinas of several species, however, the nature of the interaction of AChE with specific inhibitors are very limited in the literature and the mode of inhibition of camel retinal AChE by hexamethonium has been studied.	Hexamethonium	252-265	acetylcholinesterase	Camelus bactrianus	135-139
9502051-2	1997	Hexamethonium reversibly inhibited AChE in a concentration dependent manner, the IC50 value being c. 2.52 mM.	Hexamethonium	0-13	acetylcholinesterase	Camelus bactrianus	35-39
9311665-6	1997	The inhibitory effect of peptide YY was suppressed, or strongly and significantly reduced, by tetrodotoxin, hexamethonium, lidocaine, idazoxan and BMY14,802 (51-(4-fluorophenyl)-4-(-4-(5-fluoro-2pyrimidinyl)-1-piperazinyl)- 1-butanol), whereas devazepide and L-NAME (L-omega-N-arginine methyl ester) had no effect.	Hexamethonium	108-121	peptide YY	Rattus norvegicus	25-35
9049141-3	1997	Postprandial PYY release was suppressed or strongly decreased by caecocolonectomy, truncal vagotomy, tetrodotoxin, hexamethonium, sensory denervation by perivagal capsaicin, and by the NO-synthase inhibitor L-N-arginine methyl ester, while atropine, adrenergic blockers, antagonists of type-A or type-B cholecystokinin (CCK) receptors or bombesin receptors had no effect.	Hexamethonium	115-128	peptide YY	Rattus norvegicus	13-16
8944704-6	1996	Pretreatment of rats with the CRF antagonist alpha-helical-CRF9-41, hexamethonium, atropine, or bretylium, or the mast cell stabilizer lodoxamide inhibited stress-induced release of RMCP II, PGE2, and mucin, whereas indomethacin prevented mucin release but not mast cell degranulation.	Hexamethonium	68-81	mast cell protease 2	Rattus norvegicus	182-189
8942723-7	1996	In vivo, exogenous p-motilin stimulated endogenous c-motilin release and gastric and duodenal phase III-like contractions; this motilin-induced motilin release was inhibited by atropine, hexamethonium, and a 5-hydroxy-tryptamine 3 receptor antagonist.	Hexamethonium	187-200	motilin	Canis lupus familiaris	21-28
8968331-7	1996	The vasoactive intestinal peptide (VIP) receptor antagonist, VIP-10-28, and the muscarinic antagonist, atropine, individually reduced and together abolished the response to carbacyclin, whereas the nicotinic blocker, hexamethonium, reduced the carbacyclin response by 75%.	Hexamethonium	217-230	vasoactive intestinal peptide	Homo sapiens	35-38
8901671-9	1996	Hexamethonium (20 mg/kg IV) did not alter protection by 15-minute CAO, but it abolished protection by 15-minute MAO.	Hexamethonium	0-13	monoamine oxidase A	Rattus norvegicus	112-115
8799571-5	1996	Ascending excitatory reflexes evoked by either distension from the serosal side or compression of the mucosa were depressed by 55% and 85%, respectively, in the presence of hexamethonium (200 microM) and by 30% and 45%, respectively, by a desensitizing concentration of the selective NK3 receptor agonist, senktide (1 microM), in the chamber in which reflexes were initiated.	Hexamethonium	173-186	neuromedin-K receptor	Cavia porcellus	284-296
8859008-14	1996	Hexamethonium or L-NNA (but not atropine) reduced VIP release; CCK8 still enhanced it.	Hexamethonium	0-13	vasoactive intestinal peptide	Canis lupus familiaris	50-53
8638720-4	1996	Sulfated CCK-8 (S-CCK-8) and nonsulfated CCK-8 initiated or increased ongoing fast excitatory postsynaptic potential (fEPSP) activity, an effect antagonized by hexamethonium.	Hexamethonium	160-173	cholecystokinin	Homo sapiens	9-12
7616447-4	1995	These effects of NPFF were also observed, although attenuated, in catecholamine-depleted rats and in rats pretreated with a ganglionic blocking agent, hexamethonium (10 mg/kg, i.v.).	Hexamethonium	151-164	neuropeptide FF-amide peptide precursor	Rattus norvegicus	17-21
8605958-1	1995	In whole segments of rabbit distal colon with mucosa removed, descending reflex relaxations of the circular muscle (descending inhibition) elicited by inflating (0.1-1 ml) an intraluminal balloon, were partially antagonized by 100 microM hexamethonium and the 5-HT3 receptor antagonist, ondansetron (3 microM), and abolished by 1 microM tetrodotoxin.	Hexamethonium	238-251	5-hydroxytryptamine receptor 3A	Oryctolagus cuniculus	260-274
8584419-10	1995	Hexamethonium suppressed PYY release induced by the intraduodenal meal, but did not change PYY release induced by glucose or oleic acid in the colon.	Hexamethonium	0-13	peptide YY	Rattus norvegicus	25-28
8568687-4	1995	Refeeding of fasted rats induced a transient increase in c-fos mRNA abundance in gastric corpus and antrum that was sixfold within 15 min and declined within 4 h. The response was not mediated by gastrinergic or muscarinic cholinergic mechanisms; it was reduced but not abolished by hexamethonium.	Hexamethonium	283-296	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	57-62
8637413-6	1996	Hexamethonium only induced a significant decrease in the number of defecations (ND) induced by CCK-8s.	Hexamethonium	0-13	cholecystokinin	Gallus gallus	95-98
7574008-6	1995	Hexamethonium is known to be a weak antagonist at the postsynaptic nicotinic acetylcholine receptor but a potent antagonist at the presynaptic nicotinic receptor.	Hexamethonium	0-13	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	67-99
8779278-2	1995	Conformational and geometrical properties of the hexamethylenebis(trimethylammonium) (CH3)3N+-(CH2)6)-N+(CH3)3 (hexamethonium) and its derivatives with various degree of conformational flexibility of interonion chain having disulfide or two dimethylsilane groups or difluoromethylene chain instead of cholinesterase reversible inhibitors have been determined using molecular mechanics methods.	Hexamethonium	112-125	butyrylcholinesterase	Homo sapiens	301-315
7611400-7	1995	Pretreatment with hexamethonium (10 mg/kg) markedly reduced gastric motor response to secretin (5.6 pmol.kg-1.h-1).	Hexamethonium	18-31	secretin	Rattus norvegicus	86-94
7977833-5	1994	The increases in heart rate and lymph VIP output were blocked by hexamethonium.	Hexamethonium	65-78	vasoactive intestinal peptide	Canis lupus familiaris	38-41
7602539-12	1995	Hexamethonium abolished vagal-stimulated NO production and VIP release.	Hexamethonium	0-13	vasoactive intestinal peptide	Rattus norvegicus	59-62
7539845-10	1995	In line with this it was shown that the SP-evoked release of VIP was also significantly diminished by hexamethonium.	Hexamethonium	102-115	tachykinin precursor 1	Homo sapiens	40-42
7539845-10	1995	In line with this it was shown that the SP-evoked release of VIP was also significantly diminished by hexamethonium.	Hexamethonium	102-115	vasoactive intestinal peptide	Homo sapiens	61-64
7512633-4	1994	Selective nicotinic and muscarinic antagonists (hexamethonium and atropine) each partially reduce carbachol-stimulated increases in PNMT mRNA while a combination of both eliminates > 90% of the carbachol response, thus indicating that separable nicotinic and muscarinic components contribute to the cholinergic increase in PNMT mRNA.	Hexamethonium	48-61	phenylethanolamine N-methyltransferase	Bos taurus	132-136
7924732-6	1994	The HCO3- secretion during a single intravenous infusion of VIP (12 nmol/kg/hr), 13.9 +/- 4.2 mumol/cm/hr, was unchanged by atropine, reduced to 10.0 +/- 3.5 mumol/cm/hr by hexamethonium, and augmented to 18.9 +/- 4.7 mumol/cm/hr by indomethacin.	Hexamethonium	173-186	vasoactive intestinal peptide	Rattus norvegicus	60-63
7924732-8	1994	HCl-induced increases in luminal outputs of VIP, substance P, and neurokinin A (the two latter with unknown roles) were differentially affected by atropine, hexamethonium, and indomethacin, indicating that the acid challenge released the peptides through controlled mechanisms.	Hexamethonium	157-170	vasoactive intestinal peptide	Rattus norvegicus	44-47
7915699-4	1994	RESULTS: Lidocaine, hexamethonium, and capsaicin, but not atropine, inhibited toxin A-mediated secretion and MPO activity, but only capsaicin reduced mannitol permeability.	Hexamethonium	20-33	myeloperoxidase	Rattus norvegicus	109-112
7959408-6	1994	The potentiation of the acid secretory response to CCK-8 by the CCKA antagonist was completely blocked by vagotomy or atropine, as well as hexamethonium.	Hexamethonium	139-152	cholecystokinin	Rattus norvegicus	51-54
8089398-2	1994	In blood-perfused ileum, ACh (2-200 nmol/min) produced a dose-dependent increase in venous VIP output, which was slightly reduced by hexamethonium (10 nmol/min) and blocked by hexamethonium and atropine (10 nmol/min) in combination.	Hexamethonium	133-146	vasoactive intestinal peptide	Canis lupus familiaris	91-94
8089398-2	1994	In blood-perfused ileum, ACh (2-200 nmol/min) produced a dose-dependent increase in venous VIP output, which was slightly reduced by hexamethonium (10 nmol/min) and blocked by hexamethonium and atropine (10 nmol/min) in combination.	Hexamethonium	176-189	vasoactive intestinal peptide	Canis lupus familiaris	91-94
8089398-4	1994	ACh-induced VIP output was decreased slightly by hexamethonium (0.1 mM), and blocked by atropine (0.1 mM) or pirenzepine (0.1 mM).	Hexamethonium	49-62	vasoactive intestinal peptide	Canis lupus familiaris	12-15
8089398-5	1994	Dimethylphenylpiperazinium (0.1 mM) also caused a small increase in VIP output sensitive to hexamethonium in the ileal tissues containing either the submucous or myenteric plexus.	Hexamethonium	92-105	vasoactive intestinal peptide	Canis lupus familiaris	68-71
7524066-5	1994	Amylase release in response to submaximal concentrations of GRP were significantly inhibited by tetrodotoxin (78 +/- 5% of control) or hexamethonium (71 +/- 5% of control).	Hexamethonium	135-148	gastrin releasing peptide	Rattus norvegicus	60-63
7512633-4	1994	Selective nicotinic and muscarinic antagonists (hexamethonium and atropine) each partially reduce carbachol-stimulated increases in PNMT mRNA while a combination of both eliminates > 90% of the carbachol response, thus indicating that separable nicotinic and muscarinic components contribute to the cholinergic increase in PNMT mRNA.	Hexamethonium	48-61	phenylethanolamine N-methyltransferase	Bos taurus	326-330
18475595-4	1994	Neurogenic pathways were also involved since pretreatment of ileum with hexamethonium, hemicholinium or tetrodotoxin impaired the contractile effect of interferon gamma.	Hexamethonium	72-85	interferon gamma	Rattus norvegicus	152-168
7913213-4	1994	Hexamethonium (100 microM) completely abolished the nicotine-induced increase in DBI mRNA expression.	Hexamethonium	0-13	diazepam binding inhibitor, acyl-CoA binding protein	Homo sapiens	81-84
8113980-8	1994	Hexamethonium and atropine abolished tonic VIP output, leaving intact motility responses to PL017 and DPDPE.	Hexamethonium	0-13	vasoactive intestinal peptide	Canis lupus familiaris	43-46
8304456-8	1994	Atropine reduced and hexamethonium nearly abolished VIP output.	Hexamethonium	21-34	vasoactive intestinal peptide	Canis lupus familiaris	52-55
8128898-8	1993	On the other hand, the ODC activity of control segments were decreased by hexamethonium or atropine.	Hexamethonium	74-87	ornithine decarboxylase 1	Rattus norvegicus	23-26
8278624-3	1993	Atropine, hexamethonium and atropine plus hexamethonium treatment blocked food-induced release of PYY significantly.	Hexamethonium	10-23	peptide YY	Canis lupus familiaris	98-101
8278624-3	1993	Atropine, hexamethonium and atropine plus hexamethonium treatment blocked food-induced release of PYY significantly.	Hexamethonium	42-55	peptide YY	Canis lupus familiaris	98-101
8278624-4	1993	Integrated release of PYY in response to food alone and in combination with atropine, hexamethonium and atropine plus hexamethonium were 8.8 +/- 2.2, -1.1 +/- 2.3, -2.7 +/- 2.2 and -3.2 +/- 3.1 (ng (0-150) min/ml), respectively.	Hexamethonium	86-99	peptide YY	Canis lupus familiaris	22-25
7902011-6	1993	Hexamethonium partially blocked gastric inhibition induced by CCK.	Hexamethonium	0-13	cholecystokinin	Gallus gallus	62-65
7511424-3	1993	The ganglionic nicotine antagonist hexamethonium promoted a partial reversal of the inhibitory effect of nicotine on basal or hCG-stimulated T secretion.	Hexamethonium	35-48	hypertrichosis 2 (generalised, congenital)	Homo sapiens	126-129
8143235-7	1993	In the presence of hexamethonium, a nicotinic antagonist, PP (i.v.)	Hexamethonium	19-32	pancreatic polypeptide	Rattus norvegicus	58-60
8134298-4	1993	A combination of atropine and hexamethonium eliminated the PYY-induced decrement in VIP output and left motor excitation unchanged.	Hexamethonium	30-43	peptide YY	Canis lupus familiaris	59-62
8134298-4	1993	A combination of atropine and hexamethonium eliminated the PYY-induced decrement in VIP output and left motor excitation unchanged.	Hexamethonium	30-43	vasoactive intestinal peptide	Canis lupus familiaris	84-87
8099499-1	1993	Influence of inorganic salts on the interaction of cobra venom acetylcholinesterase (EC 3.1.1.7) with hexamethonium and gallamine has been studied.	Hexamethonium	102-115	acetylcholinesterase (Cartwright blood group)	Homo sapiens	63-83
8335198-6	1993	Atropine, hexamethonium, ICS205-930, BRL43694, phentolamine, yohimbine, and propranolol significantly inhibited motilin-induced contractions.	Hexamethonium	10-23	motilin	Canis lupus familiaris	112-119
8100836-5	1993	Pretreatment with atropine or hexamethonium completely abolished pancreatic protein response to low doses of CCK-8 (10-40 pmol/kg per h) but had only partial effect on doses > 40 pmol/kg per h. Bilateral vagotomy also abolished the pancreatic responses to low doses of CCK-8.	Hexamethonium	30-43	cholecystokinin	Rattus norvegicus	109-112
8100836-5	1993	Pretreatment with atropine or hexamethonium completely abolished pancreatic protein response to low doses of CCK-8 (10-40 pmol/kg per h) but had only partial effect on doses > 40 pmol/kg per h. Bilateral vagotomy also abolished the pancreatic responses to low doses of CCK-8.	Hexamethonium	30-43	cholecystokinin	Rattus norvegicus	272-275
8366251-8	1993	The increased responses after hexamethonium administration were augmented probably because of the enhanced release of other neuropeptides like SP and CGRP especially at 10 Hz and 20 Hz stimulation.	Hexamethonium	30-43	calcitonin-related polypeptide alpha	Rattus norvegicus	150-154
8104355-5	1993	Intravenous administration of hexamethonium significantly stimulated hydroelectrolyte secretion (from 6.99 to 15.15 microliters/min) and the plasma levels of VIP (from 4.8 to 7.3 fmol/ml) and reduced the protein output (from 61.47 to 30.75 micrograms/min) and the plasma levels of CCK (from 14.56 to 6.25 fmol/ml) in the intraduodenally perfused group.	Hexamethonium	30-43	VIP peptides	Oryctolagus cuniculus	158-161
8104355-5	1993	Intravenous administration of hexamethonium significantly stimulated hydroelectrolyte secretion (from 6.99 to 15.15 microliters/min) and the plasma levels of VIP (from 4.8 to 7.3 fmol/ml) and reduced the protein output (from 61.47 to 30.75 micrograms/min) and the plasma levels of CCK (from 14.56 to 6.25 fmol/ml) in the intraduodenally perfused group.	Hexamethonium	30-43	cholecystokinin	Oryctolagus cuniculus	281-284
7694432-3	1993	Pretreatment of the animals with hexamethonium significantly reduced GAL- and GHRH-induced GH secretion, but UK 14304-induced GH release was not affected.	Hexamethonium	33-46	galanin and GMAP prepropeptide	Rattus norvegicus	69-72
7694432-3	1993	Pretreatment of the animals with hexamethonium significantly reduced GAL- and GHRH-induced GH secretion, but UK 14304-induced GH release was not affected.	Hexamethonium	33-46	growth hormone releasing hormone	Rattus norvegicus	78-82
7694432-3	1993	Pretreatment of the animals with hexamethonium significantly reduced GAL- and GHRH-induced GH secretion, but UK 14304-induced GH release was not affected.	Hexamethonium	33-46	gonadotropin releasing hormone receptor	Rattus norvegicus	78-80
7694432-3	1993	Pretreatment of the animals with hexamethonium significantly reduced GAL- and GHRH-induced GH secretion, but UK 14304-induced GH release was not affected.	Hexamethonium	33-46	gonadotropin releasing hormone receptor	Rattus norvegicus	91-93
8365651-8	1993	On the contrary, the ganglion blocker significantly (P < 0.01) reduced plasma VIP levels in response to intraduodenal HCl (maximum response 320 +/- 74% in untreated vs 184 +/- 44% in hexamethonium-treated animals).	Hexamethonium	186-199	VIP peptides	Oryctolagus cuniculus	81-84
8097875-6	1993	Atropine and hexamethonium suppressed the stimulatory effect of neurotensin on volume, bicarbonate, and total protein output (p < 0.01).	Hexamethonium	13-26	neurotensin	Rattus norvegicus	64-75
8447490-4	1993	During autonomic blockade with methscopolamine and hexamethonium, the pressor sensitivities to AVP and [Phe2,Orn8]oxytocin were similarly increased.	Hexamethonium	51-64	arginine vasopressin	Rattus norvegicus	95-98
8099499-3	1993	The ZL psi+Z values for the complex formation between native acetylcholinesterase and hexamethonium (ZL = +2) or gallamine (ZL = +3) were in quantitative agreement with those predicted by the theory making use of psi+1 = 0.50 found earlier from the influence of salts upon the hydrolysis of acetylcholine by the enzyme.	Hexamethonium	86-99	acetylcholinesterase (Cartwright blood group)	Homo sapiens	61-81
8093875-4	1993	Intracolonic infusion of a mixture of tryptophan and phenylalanine (Trp+Phe; 100 mM; 200 ml/h) resulted in a significant release of PYY [integrated PYY release, 74.5 +/- 14.0 ng (0-120 min)/ml], which was not affected by iv atropine, hexamethonium, or propranolol treatment.	Hexamethonium	234-247	peptide YY	Canis lupus familiaris	132-135
1422856-7	1992	c-fos expression was substantially attenuated in the superficial gray layer of superior colliculus, medial terminal nucleus of the accessory optic tract, and the interpeduncular nucleus by pretreatment with the centrally acting nicotine antagonist mecamylamine, 5 mg/kg IP, but not with the peripherally acting antagonist hexamethonium, 4 mg/kg IP.	Hexamethonium	322-335	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	0-5
1355917-13	1992	In a supplementary experiment, to evaluate the role of the autonomic nervous system in plasma NPY responses, treatment with the ganglion blocker hexamethonium was shown to significantly attenuate stress-induced changes in NPY, NE, and E.	Hexamethonium	145-158	neuropeptide Y	Rattus norvegicus	94-97
1397041-4	1992	The infusion of single doses of ANGII in control, adrenalectomized, guanethidine-treated and hexamethonium-treated rats dose dependently increased MAP to similar maxima; ED50 value was increased by adrenalectomy but unaffected by guanethidine nor hexamethonium.	Hexamethonium	93-106	angiotensinogen	Rattus norvegicus	32-37
1397041-4	1992	The infusion of single doses of ANGII in control, adrenalectomized, guanethidine-treated and hexamethonium-treated rats dose dependently increased MAP to similar maxima; ED50 value was increased by adrenalectomy but unaffected by guanethidine nor hexamethonium.	Hexamethonium	247-260	angiotensinogen	Rattus norvegicus	32-37
1397041-7	1992	In hexamethonium-treated rats, ANGII also dose relatedly increased MCFP which reached similar maximum as that in control rats, but the ED50 value was reduced.	Hexamethonium	3-16	angiotensinogen	Rattus norvegicus	31-36
1355917-13	1992	In a supplementary experiment, to evaluate the role of the autonomic nervous system in plasma NPY responses, treatment with the ganglion blocker hexamethonium was shown to significantly attenuate stress-induced changes in NPY, NE, and E.	Hexamethonium	145-158	neuropeptide Y	Rattus norvegicus	222-225
1715014-4	1991	The apparent mean open time of the AChR channel, as estimated from the power density spectrum of the ACh-induced current fluctuations at -90 mV, was not decreased by 2 microM (+)-sparteine, in contrast to what was observed with hexamethonium, the well known open-channel blocker for ganglionic AChRs.	Hexamethonium	228-241	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	35-39
1347741-4	1992	PP only increased by 31 +/- 10 pg/ml during similar hypoglycemia in 7 hexamethonium-treated rats (P less than 0.01 vs. control animals).	Hexamethonium	70-83	pancreatic polypeptide	Rattus norvegicus	0-2
1729436-9	1992	In contrast, the stimulus-induced expression of Fos immunoreactivity was inhibited, but not abolished, by hexamethonium, which limited the spread of activation within the submucosal plexus and completely prevented expression of Fos immunoreactivity by myenteric neurons in response to mucosal puffs of N2.	Hexamethonium	106-119	proto-oncogene c-Fos	Cavia porcellus	48-51
1729436-9	1992	In contrast, the stimulus-induced expression of Fos immunoreactivity was inhibited, but not abolished, by hexamethonium, which limited the spread of activation within the submucosal plexus and completely prevented expression of Fos immunoreactivity by myenteric neurons in response to mucosal puffs of N2.	Hexamethonium	106-119	proto-oncogene c-Fos	Cavia porcellus	228-231
1731050-9	1992	In the presence of verapamil, ET-1 markedly raised MCFP, and this was abolished by concurrent treatment with either hexamethonium or phentolamine.	Hexamethonium	116-129	endothelin 1	Rattus norvegicus	30-34
1687814-5	1991	In the presence of hexamethonium, the pressor effect of NPY was enhanced, the lack of MCFP effect remained and the bradycardic effect was markedly attenuated.	Hexamethonium	19-32	neuropeptide Y	Rattus norvegicus	56-59
1937665-5	1991	Correspondingly, maximum response to hexamethonium bromide, a ganglion blocker, was greater in sodium chloride-loaded angiotensin II rats (77.7 +/- 4.6 mm Hg) than that in angiotensin II (59.7 +/- 5.1 mm Hg) or in sodium citrate-loaded angiotensin II (57.7 +/- 4.2 mm Hg) rats.	Hexamethonium	37-58	angiotensinogen	Rattus norvegicus	118-132
1682196-6	1991	Hexamethonium markedly reduced the ANS response to insulin injection (delta EPI +2130 +/- 600 pM, P less than 0.025 vs. control) despite a similar fall of plasma glucose (delta -4.1 +/- 0.2 mM) and a lower nadir (0.6 +/- 0.1 mM).	Hexamethonium	0-13	insulin	Canis lupus familiaris	51-58
1678851-6	1991	The nicotinic receptor antagonists hexamethonium and mecamylamine partially inhibit the nicotine-mediated stimulation of the tyrosine hydroxylase gene.	Hexamethonium	35-48	tyrosine hydroxylase	Rattus norvegicus	125-145
1848199-3	1991	Peptide YY [0.1-1000 nmol/L; concentration of half-maximal effect (EC50), 6 nmol/L] caused concentration-dependent relaxation of longitudinally oriented muscle strips that was unaffected by hexamethonium but was blocked by atropine and tetrodotoxin, suggesting that the peptide inhibited postganglionic cholinergic neurotransmission.	Hexamethonium	190-203	peptide YY	Cavia porcellus	0-10
1377730-5	1992	Also acetylcholine infusion causes a significant release of SP and NKA after infusion of both atropine and phentolamine (to 172 +/- 56% and 232 +/- 69% of basal release, n = 7), an effect that was abolished by hexamethonium infusion.	Hexamethonium	210-223	tachykinin precursor 1	Homo sapiens	60-62
1377730-5	1992	Also acetylcholine infusion causes a significant release of SP and NKA after infusion of both atropine and phentolamine (to 172 +/- 56% and 232 +/- 69% of basal release, n = 7), an effect that was abolished by hexamethonium infusion.	Hexamethonium	210-223	tachykinin precursor 1	Homo sapiens	67-70
1529272-6	1992	The inhibitory effect of PACAP was not affected by hexamethonium and was additive to the inhibitory effect of atropine and pirenzepine.	Hexamethonium	51-64	adenylate cyclase activating polypeptide 1	Rattus norvegicus	25-30
1579660-9	1992	Further evidence for a nicotinic component in the regulation of NPY-IR secretion was obtained by the finding of hexamethonium-induced reduction in basal secretion and stimulation of secretion by 1,1-dimethyl-4-phenyl-piperazinium (DMPP).	Hexamethonium	112-125	neuropeptide Y	Rattus norvegicus	64-67
1379491-5	1992	Ganglionic blockade by hexamethonium markedly inhibited Ache activity in adrenals of non-immobilized and of immobilized mice.	Hexamethonium	23-36	acetylcholinesterase	Mus musculus	56-60
1347640-6	1992	The marginal effects of large doses of nicotine on both cAMP accumulation and TH induction were blocked completely by hexamethonium but were also partially inhibited by the VIP antagonist [p-chloro-D-Phe6,Leu17]-VIP.	Hexamethonium	118-131	tyrosine hydroxylase	Bos taurus	78-80
1351787-2	1992	Mean blood pressure (MBP was maintained at a level of 100 mmHg by continuous infusion of methoxamine and hexamethonium to block autonomic outflow.	Hexamethonium	105-118	myelin basic protein	Rattus norvegicus	21-24
1681736-5	1991	Pretreatment with atropine or hexamethonium antagonized GB responses to low doses of CCK-8 (2.5-5 ng.kg-1.min-1) but had no effect on doses greater than 10 ng.kg-1.min-1.	Hexamethonium	30-43	cholecystokinin	Cavia porcellus	85-88
1681990-5	1991	Acetylcholine at concentrations of 1 to 100 nM caused a dose-dependent, rapid increase in AVP, whereas AVP release induced by 10 nM acetylcholine was completely suppressed by the combined presence of 10 microM hexamethonium, a nicotinic receptor antagonist, and 50 microM atropine, a muscarinic receptor antagonist.	Hexamethonium	210-223	arginine vasopressin	Rattus norvegicus	90-93
1681990-5	1991	Acetylcholine at concentrations of 1 to 100 nM caused a dose-dependent, rapid increase in AVP, whereas AVP release induced by 10 nM acetylcholine was completely suppressed by the combined presence of 10 microM hexamethonium, a nicotinic receptor antagonist, and 50 microM atropine, a muscarinic receptor antagonist.	Hexamethonium	210-223	arginine vasopressin	Rattus norvegicus	103-106
1717869-4	1991	Pretreatment with HEX (3 or 15 mg/kg BW), TEA (15 mg/kg BW) or PIR (0.5 mg/kg BW) significantly reduced the GAL-induced GH secretion.	Hexamethonium	18-21	galanin and GMAP prepropeptide	Rattus norvegicus	108-111
1717869-6	1991	reversed the inhibition of GAL-induced GH secretion by HEX.	Hexamethonium	55-58	galanin and GMAP prepropeptide	Rattus norvegicus	27-30
1674644-8	1991	Ganglionic blockade with hexamethonium bromide prevented the effect of ANG II injection in the RVLM.	Hexamethonium	25-46	angiotensinogen	Rattus norvegicus	71-77
20504743-3	1991	Guanethidine and hexamethonium pretreatment significantly reduced the increase of MBP induced by ET-1 but was inactive in antagonizing inhibition of SMR.	Hexamethonium	17-30	endothelin 1	Rattus norvegicus	97-101
1981173-5	1990	The cardioacceleration elicited by intrathecal CGRP was attenuated by intrathecal lidocaine administration and by combined bilateral vagotomy/hexamethonium treatment, but not by either treatment alone.	Hexamethonium	142-155	calcitonin-related polypeptide alpha	Rattus norvegicus	47-51
1970534-10	1990	In the acute studies in anesthetized animals, an intravenous bolus dose of CCK-OP (800 ng/kg) caused a substantial increase in SO spike-burst rate that was antagonized by CR1409 but not by atropine, hexamethonium, methysergide, L364718, or TTX.	Hexamethonium	199-212	cholecystokinin	Homo sapiens	75-78
1977325-5	1990	Hexamethonium blocked the changes in HR in response to VIC, whereas the ganglionic blocker, meclofenamate, or glybenclamide had no effect on changes in AP, SVR, and PVR elicited by the peptide.	Hexamethonium	0-13	endothelin 2	Mus musculus	55-58
1972607-5	1990	Tetrodotoxin, hexamethonium and methionine enkephalin inhibited both the induced VIP release and the secretory response.	Hexamethonium	14-27	vasoactive intestinal peptide	Homo sapiens	81-84
1979353-5	1990	The AChE inhibitors eserine and hexamethonium were competitive inhibitors of the membrane-bound enzyme, whereas lidocaine was a noncompetitive inhibitor; these results were comparable to the effect of these inhibitors on diaphragm muscle AChE.	Hexamethonium	32-45	acetylcholinesterase	Bos taurus	4-8
1972192-10	1990	Bradykinin-induced stimulation of tracheal ciliary beat frequency is blocked by hexamethonium bromide, ipratropium bromide or indomethacin.	Hexamethonium	80-101	kininogen 1	Canis lupus familiaris	0-10
2162234-4	1990	The hypertensive effect of intrathecal and intravenous Leu-Enk administration was blocked by prior systemic administration (10 mg/kg) of the nicotinic ganglion blocker hexamethonium, suggesting that the effect was mediated via sympathetic activation.	Hexamethonium	168-181	proenkephalin	Rattus norvegicus	59-62
2113409-4	1990	administration of TRH (0.6 and 3 nmol) at the T8-10 vertebral level resulted in a dose-related increase in epinephrine (E), norepinephrine (NE), and glucose levels, which was suppressed by prior administration of the ganglionic blocker, hexamethonium (1.5 mg/100 g b.	Hexamethonium	237-250	thyrotropin releasing hormone	Rattus norvegicus	18-21
1981792-3	1990	When arginine vasopressin was infused intravenously at a rate of 12.5 ng/(kg.min), the increase in hindquarter resistance, calculated as arterial pressure divided by hindquarter flow, was significantly (p less than 0.005) augmented after ganglionic blockade with hexamethonium in SHR but not in NCR.	Hexamethonium	263-276	arginine vasopressin	Rattus norvegicus	14-25
1967914-5	1990	Since hexamethonium almost completely blocked both insulin and glucagon responses to stimulation, the effects are not likely to have resulted from inadvertent antidromic excitation of vagal afferents.	Hexamethonium	6-19	insulin	Homo sapiens	51-58
2113965-6	1990	The responses to ET-3 were abolished by hexamethonium chloride, but were not conspicuously altered by arginine vasopressin antagonist or angiotensin II antagonist.	Hexamethonium	40-62	endothelin 3	Rattus norvegicus	17-21
2314482-5	1990	When the medium contained calcium (catechol-O-methyl transferase inhibited, all other mechanisms intact), 100 (but not 10) mumol/l DMPP induced a hexamethonium-sensitive release of 3H-noradrenaline of short duration.	Hexamethonium	146-159	catechol-O-methyltransferase	Rattus norvegicus	35-64
34924113-4	2022	A 100 muM of nicotine-induced increase in neurite numbers depended on the exposure time and was inhibited by treatment with the nAChR antagonist hexamethonium (Hex) and alpha7 nAChR antagonist alpha-bungarotoxin (alpha-Bgtx).	Hexamethonium	145-158	cholinergic receptor nicotinic beta 1 subunit	Rattus norvegicus	128-133
34924113-4	2022	A 100 muM of nicotine-induced increase in neurite numbers depended on the exposure time and was inhibited by treatment with the nAChR antagonist hexamethonium (Hex) and alpha7 nAChR antagonist alpha-bungarotoxin (alpha-Bgtx).	Hexamethonium	160-163	cholinergic receptor nicotinic beta 1 subunit	Rattus norvegicus	128-133
34273166-11	2021	Using nicotinic acetylcholine receptor (nAChR) blockers alpha-bungarotoxin and hexamethonium bromide we found that the effects of nicotine on intracellular Ca2+ and oxidative stress were mediated by alpha7 and alpha3 nAChR.	Hexamethonium	79-100	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	6-38
34273166-11	2021	Using nicotinic acetylcholine receptor (nAChR) blockers alpha-bungarotoxin and hexamethonium bromide we found that the effects of nicotine on intracellular Ca2+ and oxidative stress were mediated by alpha7 and alpha3 nAChR.	Hexamethonium	79-100	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	40-45
2569919-8	1989	The responses to GLU (10 pmol) and TRH (10 pmol) were abolished by hexamethonium and vagotomy; atropine abolished the effect of TRH and attenuated that of GLU.	Hexamethonium	67-80	thyrotropin releasing hormone	Rattus norvegicus	35-38
35231469-4	2022	Nicotine-induced depression in sensory stimulation-evoked MLI-PC synaptic transmission was abolished by either a non-selective nAChR blocker, hexamethonium, or the alpha7-nAChR antagonist methyllycaconitine (MLA), but not the selective alpha4beta2-nAChR antagonist dihydro-beta-erythroidine.	Hexamethonium	142-155	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	127-132
35231469-4	2022	Nicotine-induced depression in sensory stimulation-evoked MLI-PC synaptic transmission was abolished by either a non-selective nAChR blocker, hexamethonium, or the alpha7-nAChR antagonist methyllycaconitine (MLA), but not the selective alpha4beta2-nAChR antagonist dihydro-beta-erythroidine.	Hexamethonium	142-155	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	248-253
2482449-13	1989	Although the bradycardia elicited by [beta-Asp4, MePhe7]NKB (4-10) (32.5 nmol/kg) was also blocked by hexamethonium, methylatropine, and by bilateral vagotomy, it remained unaffected after indomethacin, or in rats pretreated with either capsaicin or compound 48/80.	Hexamethonium	102-115	tachykinin precursor 3	Rattus norvegicus	56-59
2758227-8	1989	This carbachol-evoked increase in acetylcholinesterase release was blocked by hexamethonium but not by atropine.	Hexamethonium	78-91	acetylcholinesterase	Cavia porcellus	34-54
2570597-5	1989	The reduction of mBP by hexamethonium injections was significantly larger in sham-operated DOCA/salt-treated rats than those of lesioned DOCA/salt rats.	Hexamethonium	24-37	myelin basic protein	Mus musculus	17-20
2472074-5	1989	Prior close intra-arterial administration of hexamethonium significantly enhanced the colonic motor response to substance P.	Hexamethonium	45-58	tachykinin precursor 1	Homo sapiens	112-123
2475029-3	1989	VIP release was markedly reduced by tetrodotoxin, perfusion with Ca-free medium, or by hexamethonium but not by atropine.	Hexamethonium	87-100	vasoactive intestinal peptide	Canis lupus familiaris	0-3
2912212-4	1989	In contrast, in anesthesized rats the arterial pressor response to intrathecal AVP was blocked by intrathecal V1-ANT, intravenous hexamethonium, and intravenous phenoxybenzamine.	Hexamethonium	130-143	arginine vasopressin	Rattus norvegicus	79-82
2787038-4	1989	Tetrodotoxin and hexamethonium abolished the effects of CGRP on basal short-circuit current whereas atropine did not.	Hexamethonium	17-30	calcitonin related polypeptide alpha	Homo sapiens	56-60
2566102-5	1989	In contrast, the hemodynamic response to hypertonic saline was totally reverted when the vasopressin antagonist was injected in the hexamethonium-pretreated rats.	Hexamethonium	132-145	arginine vasopressin	Rattus norvegicus	89-100
2568570-4	1989	The administration of hexamethonium attenuated the changes in MAP and heart rate (HR) which occurred in response to alterations in carotid sinus pressure, and abolished the change in plasma IR-ANP.	Hexamethonium	22-35	natriuretic peptides A	Oryctolagus cuniculus	193-196
3577808-6	1987	Hexamethonium, a nicotinic receptor antagonist, inhibited the secretion elicited by the lower but not by the higher dose of NT.	Hexamethonium	0-13	neurotensin	Homo sapiens	124-126
2977989-8	1988	TRH-induced hyperinsulinemia was abolished by vagotomy and by systemic administration of hexamethonium or atropine.	Hexamethonium	89-102	thyrotropin releasing hormone	Rattus norvegicus	0-3
3346065-5	1988	The pressor response to vasopressin, but not to Ang II or norepinephrine, was greater in dexamethasone-treated than in vehicle-treated animals, and this difference became more pronounced in rats that received hexamethonium and MK 421.	Hexamethonium	209-222	arginine vasopressin	Rattus norvegicus	24-35
3259432-8	1988	The tachycardia response to central CGRP was attenuated by pretreatment with propranolol or hexamethonium, indicating that the heart rate response was mediated, in part, through increases in cardiac sympathetic tone.	Hexamethonium	92-105	calcitonin-related polypeptide alpha	Rattus norvegicus	36-40
2892605-7	1988	Interruption of the sympathetic nervous system and the vascular action of vasopressin with intravenous hexamethonium and d(CH2)5Tyr(Me)arginine vasopressin attenuated the pressor and natriuretic responses to intracerebroventricular high Na+ CSF.	Hexamethonium	103-116	arginine vasopressin	Rattus norvegicus	74-85
2889122-5	1987	On the other hand, when hexamethonium was infused, naloxone significantly inhibited both the GRP and gastrin responses to electrical vagal stimulation.	Hexamethonium	24-37	gastrin releasing peptide	Rattus norvegicus	93-96
2889122-5	1987	On the other hand, when hexamethonium was infused, naloxone significantly inhibited both the GRP and gastrin responses to electrical vagal stimulation.	Hexamethonium	24-37	gastrin	Rattus norvegicus	101-108
2886872-7	1987	When the 9 or 17 mumol Na/g diet were initiated at 2, 4, and 7 weeks of age, the response of blood pressure to hexamethonium administration was blunted in SHR relative to both WKY receiving the same diet, and to control SHR receiving 101 mumol Na/g.	Hexamethonium	111-124	sodium voltage-gated channel alpha subunit 7	Rattus norvegicus	23-27
2886872-7	1987	When the 9 or 17 mumol Na/g diet were initiated at 2, 4, and 7 weeks of age, the response of blood pressure to hexamethonium administration was blunted in SHR relative to both WKY receiving the same diet, and to control SHR receiving 101 mumol Na/g.	Hexamethonium	111-124	sodium voltage-gated channel alpha subunit 7	Rattus norvegicus	244-248
3585342-6	1987	Chrg A release on nicotinic stimulation is blocked by D-600 and hexamethonium to the same extent as Met-enkephalin and catecholamine release.	Hexamethonium	64-77	chromogranin A	Bos taurus	0-6
2903757-5	1988	The cholinesterase activity in rat diaphragm homogenates was inhibited by hexamethonium.	Hexamethonium	74-87	butyrylcholinesterase	Rattus norvegicus	4-18
3031661-2	1987	This inhibitory effect was unaffected by hexamethonium but was abolished by atropine and tetrodotoxin, suggesting that neuropeptide Y is acting via postganglionic cholinergic neurons.	Hexamethonium	41-54	pro-neuropeptide Y	Cavia porcellus	119-133
3826404-5	1987	Ganglionic blockade with methscopolamine and hexamethonium resulted in nearly a 60-fold enhancement of vasopressin pressor sensitivity.	Hexamethonium	45-58	arginine vasopressin	Rattus norvegicus	103-114
3792443-4	1986	Responses to motilin were partially inhibited by hexamethonium perfusion (15 micrograms/ml) suggesting that motilin acts, in part, on preganglionic neural elements proximal to nicotinic cholinergic synapses within the enteric nervous system.	Hexamethonium	49-62	motilin	Canis lupus familiaris	108-115
2883103-3	1987	Pretreatment subcutaneously with a ganglion-blocking dose of hexamethonium (10 mg/kg), however, inhibited nicotine-stimulated acid output and ethanol-evoked somatostatin secretion but not ethanol-induced gastrin release.	Hexamethonium	61-74	somatostatin	Rattus norvegicus	157-169
2437546-8	1987	Atropine significantly reduced, and hexamethonium abolished this VIP-output elicited by parasympathetic nerve stimulation.	Hexamethonium	36-49	VIP peptides	Oryctolagus cuniculus	65-68
3794328-5	1986	Ganglionic blockade with hexamethonium and atropine produced equivalent decreases in arterial pressure and increases in plasma vasopressin concentration in the two groups of rats.	Hexamethonium	25-38	arginine vasopressin	Rattus norvegicus	127-138
2425970-9	1986	sec-1) and the estimated dissociation (kb = 0.24-0.29 sec-1) rate constants derived from a three-state sequential model for block by hexamethonium were independent of the membrane potential.	Hexamethonium	133-146	secretory blood group 1, pseudogene	Homo sapiens	54-59
2874742-3	1986	Hexamethonium did, however, block the increase in blood pressure, the decrease in heart rate, and the very small elevation in the plasma vasopressin concentration induced by nicotine (10 micrograms icv).	Hexamethonium	0-13	arginine vasopressin	Rattus norvegicus	137-148
2875603-4	1986	injections of alpha, beta-methylene ATP (mATP) induced colonic and rectal contractions which were resistant to atropine, hexamethonium and indomethacin, as well as to the nerve blocking agent tetrodotoxin.	Hexamethonium	121-134	solute carrier family 45, member 2	Mus musculus	36-39
6296363-5	1983	The increase in plasma cyclic GMP elicited by morphine was abolished by vagotomy and pretreatment with hexamethonium and atropine and was partly inhibited by pretreatment with phentolamine.	Hexamethonium	103-116	5'-nucleotidase, cytosolic II	Mus musculus	30-33
3013108-5	1986	Inhibition of clonidine-induced increase in plasma cyclic GMP by yohimbine, hexamethonium and atropine, but not by prazosin suggests that the effect of clonidine is mediated by the central alpha 2-adrenoceptors, activating the muscarinic receptor-linked guanylate cyclase through the stimulation of vagal activity.	Hexamethonium	76-89	5'-nucleotidase, cytosolic II	Mus musculus	58-61
2880306-5	1986	Hexamethonium, but not atropine, prevented the increase in VP release produced by increased osmolality of the hypothalamus side culture medium.	Hexamethonium	0-13	arginine vasopressin	Rattus norvegicus	59-61
6150993-6	1984	Pre-treatment with hexamethonium completely abolished the rise in plasma neuropeptide Y concentrations.	Hexamethonium	19-32	neuropeptide Y	Bos taurus	73-87
6150485-9	1984	The nicotinic antagonist hexamethonium reduced the increase in 32P incorporation into tyrosine hydroxylase by about 50%, while the muscarinic antagonist atropine had no effect.	Hexamethonium	25-38	tyrosine hydroxylase	Rattus norvegicus	86-106
6326156-4	1984	Intravenous infusion of ANF in the bilaterally nephrectomized, hexamethonium-treated rat produces only a small transient pressor response, probably due to potentiation of endogenous norepinephrine.	Hexamethonium	63-76	natriuretic peptide A	Rattus norvegicus	24-27
6142392-2	1984	Tetrodotoxin infused intraarterially blocked field stimulated contractions and abolished the response to motilin as did treatment with a combination of hexamethonium and atropine.	Hexamethonium	152-165	motilin	Canis lupus familiaris	105-112
6142392-4	1984	Hexamethonium alone similarly increased the dose of motilin required in the jejunum, but not for the ileum.	Hexamethonium	0-13	motilin	Canis lupus familiaris	52-59
6696102-5	1984	The enhanced vasoconstrictor responses to carotid infusions of ANG II were significantly attenuated by systemic hexamethonium or central saralasin.	Hexamethonium	112-125	angiotensinogen	Rattus norvegicus	63-69
6139157-5	1983	Either hexamethonium or atropine blocked IR motilin release induced by stimulation of intrinsic or extrinsic nerves while only atropine inhibited the release induced by intraarterial carbachol.	Hexamethonium	7-20	motilin	Canis lupus familiaris	44-51
6196809-6	1983	The vagally induced pyloric contraction was noncholinergic, nonadrenergic, but sensitive to ganglionic blockade (hexamethonium) or the SP analogue, indicating involvement of SP in a peptidergic pathway to the sphincter.	Hexamethonium	113-126	tachykinin precursor 1	Homo sapiens	174-176
6196809-9	1983	injection of SP, was sensitive to atropine or the SP analogue but hexamethonium resistant.	Hexamethonium	66-79	tachykinin precursor 1	Homo sapiens	13-15
6679787-2	1983	These derivatives of hexamethonium and decamethonium manifested reversible inhibition (Ki approximately 100-1 microM) and irreversible alkylating activity (kII approximately 10(2) M-1 .	Hexamethonium	21-34	myoregulin	Homo sapiens	180-183
6136311-5	1983	A simultaneous perfusion of hexamethonium (1.9 x 10(-4) M/min) blocked ACh-induced VIP release.	Hexamethonium	28-41	vasoactive intestinal peptide	Rattus norvegicus	83-86
6138759-1	1983	In conscious dogs with gastric fistula and platinum electrodes on the antrum, duodenum and jejunum, IV atropine 100 micrograms/kg/hr and hexamethonium 10 mg/kg/hr, blocked cyclic increases in fasting plasma motilin concentration (PMC) and spontaneous migrating myoelectric complexes (MMCs) of both antrum and duodenum.	Hexamethonium	137-150	motilin	Canis lupus familiaris	207-214
2425187-6	1986	In the second study, Ang II-neural interactions were examined by treating 12- to 14-day postligation hypertensive rats with captopril or with hexamethonium, a ganglionic blocker, followed by captopril.	Hexamethonium	142-155	angiotensinogen	Rattus norvegicus	21-27
3907806-5	1985	At 16 weeks of age, hexamethonium caused potentiation of the blood pressure response to noradrenaline and angiotensin II, but to the same degree in the two strains.	Hexamethonium	20-33	angiotensinogen	Rattus norvegicus	106-120
4018497-10	1985	The LES response to motilin was abolished by hexamethonium and significantly antagonized by atropine and 4-diphenylacetoxy-N-methylpiperidine methiodide, but was not affected by pirenzepine, phentolamine, or naloxone.	Hexamethonium	45-58	motilin	Homo sapiens	20-27
2858978-5	1985	The infusion of hexamethonium bromide at a concentration of 10(-4) M significantly suppressed GRP release but did not affect gastrin secretion in response to vagal stimulation.	Hexamethonium	16-37	gastrin releasing peptide	Rattus norvegicus	94-97
2579749-9	1985	Peripheral alpha-adrenoceptor blockade with prazosin or ganglion blockade with hexamethonium inhibited the central angiotensin II pressor responses only in combination with vasopressin receptor blockade.	Hexamethonium	79-92	angiotensinogen	Rattus norvegicus	115-129
6191240-3	1983	The results show that the hypotensive activity of NT and of compound 48/80 (C48/80), in contrast to that of histamine, of 5-hydroxytryptamine and of hexamethonium, is markedly reduced, especially for NT, in nephrectomized as compared to sham operated rats.	Hexamethonium	149-162	neurotensin	Rattus norvegicus	50-52
6181515-3	1982	Antibodies produced in rabbits to a conjugate of bovine serum albumin and a derivative of BisQ mimicked the binding characteristics of the AcChoR with respect to the order of binding of a variety of agonists and to the preferred recognition of decamethonium ion (an agonist) over hexamethonium ion (an antagonist).	Hexamethonium	280-293	albumin	Oryctolagus cuniculus	56-69
7153911-4	1982	Efferent stimulation of the pelvic nerve caused an increase in the release of VIP, which was unaffected by atropine and adrenoceptor antagonists, but completely abolished by hexamethonium.	Hexamethonium	174-187	vasoactive intestinal peptide	Felis catus	78-81
7153911-6	1982	Efferent stimulation of the hypogastric nerves induced a marked increase in the release of VIP, which was blocked by hexamethonium.	Hexamethonium	117-130	vasoactive intestinal peptide	Felis catus	91-94
6189365-0	1982	VIP as a mediator of hexamethonium-sensitive, atropine-resistant vasodilation in the cat tongue.	Hexamethonium	21-34	vasoactive intestinal peptide	Homo sapiens	0-3
6124477-3	1982	The gastrin response was abolished by hexamethonium but only partly inhibited (35% at the higher dose of 1,1-dimethyl-4-phenylpiperazinium) by atropine.	Hexamethonium	38-51	gastrin	Rattus norvegicus	4-11
6778689-1	1981	A tetrodotoxin- and hexamethonium-sensitive response to thyrotropin-releasing hormone (TRH), an in vitro contraction, first appeared in the duodenum of the 3 day old rat, was increased by day 16, decreased there-after and was extinguished after weaning.	Hexamethonium	20-33	thyrotropin releasing hormone	Rattus norvegicus	56-85
7127212-3	1982	On the other hand, blockade of nicotinic receptors by hexamethonium treatment obliterated I gastrin release induced by stimulation of the extrinsic nerves but only reduced motility.	Hexamethonium	54-67	gastrin	Canis lupus familiaris	92-99
7127212-5	1982	Since hexamethonium treatment only slightly reduced both I gastrin release and motility and atropinization eliminated both during field stimulation, the presence of a muscarinic receptor in the final pathway for each is proposed.	Hexamethonium	6-19	gastrin	Canis lupus familiaris	59-66
6123262-6	1982	Plasma norepinephrine and epinephrine levels were not altered by PGF2 alpha-icv in hexamethonium-treated rats, but plasma vasopressin concentration was markedly elevated in all hexamethonium-infused rats.	Hexamethonium	177-190	arginine vasopressin	Rattus norvegicus	122-133
7045869-6	1982	Hexamethonium, a nicotinic antagonist, at 1 microM abolished the acetylcholine-induced increment in LH-RH release.	Hexamethonium	0-13	gonadotropin releasing hormone 1	Rattus norvegicus	100-105
6115624-3	1981	Alpha adrenoceptor antagonists, hexamethonium and 6-hydroxydopamine diminished the effectiveness of low acetylcholine concentrations on normal and castrated preparations of the epididymal portion of isolated rat vas deferens, but did not influence the maximal response.	Hexamethonium	32-45	arginine vasopressin	Rattus norvegicus	212-215
6778689-1	1981	A tetrodotoxin- and hexamethonium-sensitive response to thyrotropin-releasing hormone (TRH), an in vitro contraction, first appeared in the duodenum of the 3 day old rat, was increased by day 16, decreased there-after and was extinguished after weaning.	Hexamethonium	20-33	thyrotropin releasing hormone	Rattus norvegicus	87-90
7345899-15	1981	Hexamethonium treatment abolished both the vasodilation, the secretion and the VIP release seen during parasympathetic nerve stimulation implying that it was preganglionic and that the preganglionic transmitter is acetylcholine which activates postganglionic transmitter is acetylcholine which activates postganglionic neurons via nicotinic receptors.	Hexamethonium	0-13	vasoactive intestinal peptide	Felis catus	79-82
7470728-2	1980	2 Veratridine (100 microM) and excess K+ (56 mM) caused secretion of catecholamine and dopamine-beta-hydroxylase (DBH) activity in the venous effluents in the presence of atropine (30 microM) and hexamethonium (2 mM).	Hexamethonium	196-209	dopamine beta-hydroxylase	Cavia porcellus	87-112
7470728-2	1980	2 Veratridine (100 microM) and excess K+ (56 mM) caused secretion of catecholamine and dopamine-beta-hydroxylase (DBH) activity in the venous effluents in the presence of atropine (30 microM) and hexamethonium (2 mM).	Hexamethonium	196-209	dopamine beta-hydroxylase	Cavia porcellus	114-117
191573-10	1977	This PSP is blocked by 10(-4) g/ml hexamethonium and mimicked by a Na-dependent ACh response.	Hexamethonium	35-48	microseminoprotein beta	Homo sapiens	5-8
7440712-5	1980	The effect of OP-CCK on the gallbladder was partially blocked by tetrodotoxin (P < 0.02), hexamethonium alone (P < 0.05), or a combination of hexamethonium and atropine (P < 0.01).	Hexamethonium	93-106	cholecystokinin	Canis lupus familiaris	17-20
7440712-5	1980	The effect of OP-CCK on the gallbladder was partially blocked by tetrodotoxin (P < 0.02), hexamethonium alone (P < 0.05), or a combination of hexamethonium and atropine (P < 0.01).	Hexamethonium	148-161	cholecystokinin	Canis lupus familiaris	17-20
436724-2	1979	Nicotinic antagonists, hexamethonium, tetraethylammonium chloride, and trimethaphan blocked VP release in response to acetylcholine and nicotine.	Hexamethonium	23-36	arginine vasopressin	Rattus norvegicus	92-94
7439634-6	1980	Tetrodotoxin and hexamethonium, but not atropine, inhibited oxytocin-stimulted release of VIP by 80% and 60% respectively.	Hexamethonium	17-30	vasoactive intestinal peptide	Canis lupus familiaris	90-93
7439634-8	1980	Hexamethonium strongly inhibited neostigmine-stimulated release of VIP.	Hexamethonium	0-13	vasoactive intestinal peptide	Canis lupus familiaris	67-70
456315-2	1979	Nicotinic blocking agents, hexamethonium, tetraethylammonium chloride, and trimethaphan, blocked VP release in response to the addition of sufficient NaCl to yield a 10 mosm/kg H2O increase in culture medium osmolality.	Hexamethonium	27-40	arginine vasopressin	Rattus norvegicus	97-99
119692-5	1979	The DA releasing effect of TRH was completely blocked by cholinergic blockers (scopolamine, hexamethonium and hemicholinium), Ca2+ chelator(EGTA), Ca2+ antagonist(CoCl2) and Ca2+ influx blocker(D-600) or by the removal of Ca2+ from the medium.	Hexamethonium	92-105	thyrotropin releasing hormone	Rattus norvegicus	27-30
874847-0	1977	Effect of hexamethonium on the release of vasopressin by nicotine and carotid occlusion [proceedings].	Hexamethonium	10-23	arginine vasopressin	Homo sapiens	42-53
1186525-0	1975	Cutaneous microcirculatory responses to insulin administration in the fasted and hexamethonium-treated rabbit, with special regard to peripheral circulating leukocytes.	Hexamethonium	81-94	insulin	Oryctolagus cuniculus	40-47
177753-8	1976	In contrast, central administration of other anticholinergic drugs, such as delta-tobocurarine and hexamethonium, reduced ethanol-induced sleep and this effect was additive with TRH.	Hexamethonium	99-112	thyrotropin releasing hormone	Rattus norvegicus	178-181
1255923-7	1976	Plasma renin activity of the hexamethonium bromide treated dogs was 19.0 +/- 3.5 ng/ml during room air breathing.	Hexamethonium	29-50	renin	Canis lupus familiaris	7-12
1017712-6	1976	Hexamethonium 2 mg/kg resulted in both a diminished rise in LES pressure and the disappearance of contractions after motilin.	Hexamethonium	0-13	motilin	Canis lupus familiaris	117-124
1017712-7	1976	Hexamethonium and atropine together completely abolished the LES response to motilin.	Hexamethonium	0-13	motilin	Canis lupus familiaris	77-84
954827-3	1976	The increase in PVR to delta9-THC was significantly reduced by cardiac pacing, and was virtually abolished either by bilateral vagotomy or by pretreatment with hexamethonium.	Hexamethonium	160-173	PVR cell adhesion molecule	Canis lupus familiaris	16-19
948350-2	1976	The influence of the 2 alkane-bis-onium compounds hexafluorenium (HF1) and hexamethonium (C6) on human plasma cholinesterase (ChE) was studied with respect to the type of inhibition.	Hexamethonium	75-88	butyrylcholinesterase	Homo sapiens	110-124
1079076-4	1975	Acetylcholine (1-5 pg) caused a dose-dependent release of CRH which was antagonized by hexamethonium (1-10ng) and partially antagonized by atropine (300 pg).	Hexamethonium	87-100	corticotropin releasing hormone	Rattus norvegicus	58-61
166720-7	1975	The anti-curare effect of hexamethonium is abolished in the diaphragm of the rat, guinea-pig and mouse by inhibitors of acetylcholinesterase.	Hexamethonium	26-39	acetylcholinesterase	Mus musculus	120-140
5768107-0	1969	The effects of pempidine and hexamethonium on release of antidiuretic hormone by nicotine and osmotic stimuli in the cat.	Hexamethonium	29-42	arginine vasopressin	Homo sapiens	57-77
4447857-4	1974	Hexamethonium did not produce local anaesthesia.7 The results indicate that the facilitated release of noradrenaline after SNS and the inhibition of release after DMPP produced by McN-A-343 and AHR 602 are the result of their combined local anaesthetic action and inhibition of amine uptake.	Hexamethonium	0-13	aryl hydrocarbon receptor	Oryctolagus cuniculus	194-197
13627212-0	1959	Pressor effect of subcutaneous renin in dogs, and effect of reserpine, 1-hydrazinophthalazine and hexamethonium on renin hypertension.	Hexamethonium	98-111	renin	Canis lupus familiaris	115-120
6052783-0	1967	[Experiences with the use of hexamethonium with insulin treatment in psychiatry].	Hexamethonium	29-42	insulin	Homo sapiens	48-55
13707726-4	1961	In spinal atropinized rats injected with hexamethonium 5 mg/kg this pressor effect produced by injection of the adrenaline antagonist, compound AT3 [ethylfluoren-9-yl(2-iodoethyl)amine hydriodide], was reduced by prior treatment for five days with 1 mg/kg reserpine.	Hexamethonium	41-54	angiotensin II receptor, type 1b	Rattus norvegicus	144-147
14954123-0	1952	Effect of hexamethonium on the response to insulin in animals and man.	Hexamethonium	10-23	insulin	Homo sapiens	43-50
33456504-8	2021	The muscarinic acetylcholine receptor (mAChR) antagonist atropine (ATR; 100 nM) and the nicotinic acetylcholine receptor (nAChR) antagonist hexamethonium (HEM; 50 microM) were administered 10 min before APC.	Hexamethonium	140-153	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	122-127
33384338-8	2021	Cryoelectron microscopy analysis of the HAdV-D56 virion-CD46 complex confirmed the interaction and showed that CD46 binds to the central cavity of hexon trimers.	Hexamethonium	147-152	CD46 molecule	Homo sapiens	56-60
33384338-8	2021	Cryoelectron microscopy analysis of the HAdV-D56 virion-CD46 complex confirmed the interaction and showed that CD46 binds to the central cavity of hexon trimers.	Hexamethonium	147-152	CD46 molecule	Homo sapiens	111-115
33146235-9	2020	Administration of hexamethonium, a ganglion blocker, abolished RIP-induced increase in plasma CCK levels and cardioprotective effects.	Hexamethonium	18-31	cholecystokinin	Rattus norvegicus	94-97
31657686-6	2019	RESULTS: Infusion of apelin into PVN of Wistar-Kyoto (WKY) rats induced chronic increases in systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), plasma norepinephrine (NE) level, maximal depressor response to hexamethonium (Hex), NAD(P)H oxidase activity, superoxide anions levels, and Nox4 expression.	Hexamethonium	250-263	apelin	Rattus norvegicus	21-27
32337286-13	2020	Finally, four small molecules that could reverse the gene expression induced by thyroid cancer, namely ikarugamycin, adrenosterone, hexamethonium bromide and clofazimine, were obtained in the CMap database.	Hexamethonium	132-153	cystatin F	Homo sapiens	192-196
31657686-6	2019	RESULTS: Infusion of apelin into PVN of Wistar-Kyoto (WKY) rats induced chronic increases in systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), plasma norepinephrine (NE) level, maximal depressor response to hexamethonium (Hex), NAD(P)H oxidase activity, superoxide anions levels, and Nox4 expression.	Hexamethonium	265-268	apelin	Rattus norvegicus	21-27
31657686-8	2019	Hex, a sympathetic ganglion blocker, inhibited apelin-induced increases in SBP, DBP and MAP.	Hexamethonium	0-3	apelin	Rattus norvegicus	47-53
31657686-9	2019	SOD overexpression in PVN of SHRs inhibited the apelin-induced increase in SBP, DBP, MAP, plasma NE level, and maximal depressor response to Hex.	Hexamethonium	141-144	apelin	Rattus norvegicus	48-54
31657686-10	2019	PVN Nox4 knockdown also attenuated the apelin-induced increase in SBP, DBP, MAP, plasma NE level, and maximal depressor response to Hex.	Hexamethonium	132-135	NADPH oxidase 4	Rattus norvegicus	4-8
31657686-10	2019	PVN Nox4 knockdown also attenuated the apelin-induced increase in SBP, DBP, MAP, plasma NE level, and maximal depressor response to Hex.	Hexamethonium	132-135	apelin	Rattus norvegicus	39-45
28935683-14	2018	Short-latency calcium transients were detected in >90% of calcitonin gene-related peptide-immunoreactive neurons to electrical stimulation of hexamethonium-sensitive pathways.	Hexamethonium	145-158	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	61-92
29360991-9	2018	Increased sympathetic activity in sm-STIM1 KO mice was unmasked by apha1-adrenergic receptor inhibitor (prazosin) and by treatment with the ganglion-blocking agent, hexamethonium.	Hexamethonium	165-178	stromal interaction molecule 1	Mus musculus	37-42
26820216-6	2016	The ganglionic nicotinic receptor blocker, hexamethonium dichloride, attenuated the pressor response to Ang II, indicating that the cardiovascular sympathetic system is involved in the pressor effect of Ang II.	Hexamethonium	43-67	angiotensinogen	Rattus norvegicus	203-209
27923809-8	2017	We also found that after pretreatment with hexamethonium (n = 8), ICV leptin infusion, during continued ganglionic blockade, completely normalized blood glucose in diabetic rats.	Hexamethonium	43-56	leptin	Rattus norvegicus	70-76
27028622-10	2016	Nicotine increased the Bax/Bcl-2 ratio, which was attenuated by N-acetyl-L-cysteine, the NF-kappaB inhibitor, Bay 11-7082, and hexamethonium, a non-specific nAChR blocker.	Hexamethonium	127-140	BCL2 associated X, apoptosis regulator	Homo sapiens	23-26
26948539-5	2016	In conscious rats, unilateral BDNF (12.5ng) microinjections into the PVN increased mean arterial pressure (MAP) by 27+-1mmHg (P<0.001 vs vehicle), which was significantly attenuated by intracerebroventricular infusion of the Ang II-type-1 receptor (AT1R) antagonist losartan and by ganglionic blockade with intravenous hexamethonium infusion.	Hexamethonium	322-335	brain-derived neurotrophic factor	Rattus norvegicus	30-34
26948539-6	2016	In anesthetized rats, unilateral PVN microinjection of BDNF increased MAP by 31+-4mmHg (P<0.001 vs vehicle), which was prevented by PVN microinjection pretreatments with the high-affinity BDNF receptor TrkB antagonist ANA-12, losartan, the angiotensin converting enzyme inhibitor lisinopril, or by intravenous hexamethonium.	Hexamethonium	313-326	brain-derived neurotrophic factor	Rattus norvegicus	55-59
26820216-6	2016	The ganglionic nicotinic receptor blocker, hexamethonium dichloride, attenuated the pressor response to Ang II, indicating that the cardiovascular sympathetic system is involved in the pressor effect of Ang II.	Hexamethonium	43-67	angiotensinogen	Rattus norvegicus	104-110
26746861-9	2016	The effects of relaxin-2 on RSNA and MAP were abolished by intravenous infusion of ganglionic blocker hexamethonium, and attenuated by AVP V1 receptor antagonist AAVP.	Hexamethonium	102-115	relaxin 2	Homo sapiens	15-24
27028622-10	2016	Nicotine increased the Bax/Bcl-2 ratio, which was attenuated by N-acetyl-L-cysteine, the NF-kappaB inhibitor, Bay 11-7082, and hexamethonium, a non-specific nAChR blocker.	Hexamethonium	127-140	BCL2 apoptosis regulator	Homo sapiens	27-32
27028622-12	2016	While nicotine treatment increased the expression of phosphorylated cdc2 and histone H3, a marker of G2/M phase arrest, hexamethonium and Bay 11-7082 pretreatment reduced their expression.	Hexamethonium	120-133	cyclin dependent kinase 1	Homo sapiens	68-72
26843857-10	2016	Moreover, the inhibitory effect of AVP (180 pmol) on gastric motility could be blocked completely by both SR49059 (320 pmol) and hexamethonium (8 mumol).	Hexamethonium	129-142	arginine vasopressin	Rattus norvegicus	35-38
25948261-9	2015	Furthermore, at E12.5 we found evidence for unconventional receptors that were responsive to the nAChR agonists 1-dimethyl-4-phenylpiperazinium and nicotine, but were insensitive to the general nicotinic blocker, hexamethonium.	Hexamethonium	213-226	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	97-102
25503516-5	2015	N-acetyl-cysteine (ROS scavenger) or hexamethonium [nicotinic acetylcholine receptor (nAChR) antagonist] attenuated the CSE-induced increase in intracellular ROS, activation of AMPK and NF-kappaB, as well as IL-8 induction, which suggests that nAChRs and ROS are important.	Hexamethonium	37-50	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	52-84
25503516-5	2015	N-acetyl-cysteine (ROS scavenger) or hexamethonium [nicotinic acetylcholine receptor (nAChR) antagonist] attenuated the CSE-induced increase in intracellular ROS, activation of AMPK and NF-kappaB, as well as IL-8 induction, which suggests that nAChRs and ROS are important.	Hexamethonium	37-50	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	86-91
25503516-5	2015	N-acetyl-cysteine (ROS scavenger) or hexamethonium [nicotinic acetylcholine receptor (nAChR) antagonist] attenuated the CSE-induced increase in intracellular ROS, activation of AMPK and NF-kappaB, as well as IL-8 induction, which suggests that nAChRs and ROS are important.	Hexamethonium	37-50	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	177-181
25503516-5	2015	N-acetyl-cysteine (ROS scavenger) or hexamethonium [nicotinic acetylcholine receptor (nAChR) antagonist] attenuated the CSE-induced increase in intracellular ROS, activation of AMPK and NF-kappaB, as well as IL-8 induction, which suggests that nAChRs and ROS are important.	Hexamethonium	37-50	nuclear factor kappa B subunit 1	Homo sapiens	186-195
25503516-5	2015	N-acetyl-cysteine (ROS scavenger) or hexamethonium [nicotinic acetylcholine receptor (nAChR) antagonist] attenuated the CSE-induced increase in intracellular ROS, activation of AMPK and NF-kappaB, as well as IL-8 induction, which suggests that nAChRs and ROS are important.	Hexamethonium	37-50	C-X-C motif chemokine ligand 8	Homo sapiens	208-212
25617597-6	2015	Labeling of lt14a with an Alexa Fluor 488 ester showed that lt14a was bound to the surface of PC12 cells and that this binding was inhibited by pre-application of the nicotinic acetylcholine receptor (nAChR) antagonist tubocurarine chloride (TUB) and the nAChR blocker hexamethonium bromide (HB).	Hexamethonium	269-290	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	167-199
25617597-6	2015	Labeling of lt14a with an Alexa Fluor 488 ester showed that lt14a was bound to the surface of PC12 cells and that this binding was inhibited by pre-application of the nicotinic acetylcholine receptor (nAChR) antagonist tubocurarine chloride (TUB) and the nAChR blocker hexamethonium bromide (HB).	Hexamethonium	269-290	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	201-206
25617597-6	2015	Labeling of lt14a with an Alexa Fluor 488 ester showed that lt14a was bound to the surface of PC12 cells and that this binding was inhibited by pre-application of the nicotinic acetylcholine receptor (nAChR) antagonist tubocurarine chloride (TUB) and the nAChR blocker hexamethonium bromide (HB).	Hexamethonium	292-294	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	167-199
25617597-6	2015	Labeling of lt14a with an Alexa Fluor 488 ester showed that lt14a was bound to the surface of PC12 cells and that this binding was inhibited by pre-application of the nicotinic acetylcholine receptor (nAChR) antagonist tubocurarine chloride (TUB) and the nAChR blocker hexamethonium bromide (HB).	Hexamethonium	292-294	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	201-206
23183626-7	2013	Hexamethonium (10 mg/kg, sc) prevented Ucn 1-induced rise in total ghrelin levels while not altering the hyperglycemic response.	Hexamethonium	0-13	ghrelin and obestatin prepropeptide	Rattus norvegicus	67-74
25514605-7	2015	A pretreatment with nicotinic acetylcholine receptor antagonists hexamethonium, mecamylamine, and methyllycaconitine, but not dextrometorphan, canceled the TH-LI nerve reinnervation induced by nicotine.	Hexamethonium	65-78	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	20-52
25492829-7	2014	In contrast, when pretreated with hexamethonium, a ganglionic blocker, simvastatin and pravastatin groups showed a similar hypertensive response to Ang II, which was smaller than in controls.	Hexamethonium	34-47	angiotensinogen	Rattus norvegicus	148-154
24886596-8	2014	Behavioral analysis of ART-OE and wildtype mice showed that Artn-induced thermal hyperalgesia can be blocked by mecamylamine or hexamethonium.	Hexamethonium	128-141	artemin	Mus musculus	60-64
24578344-11	2014	VIP (100 nM) induced longitudinal muscle contraction that was inhibited by TTX (1 muM), PG97-269 (VPAC1 antagonist; 1 muM), and hyoscine (10 muM), but not by hexamethonium (200 muM).	Hexamethonium	158-171	VIP peptides	Cavia porcellus	0-3
23388515-11	2013	After hexamethonium treatment, it was found that the acute hypertension induced by 6-hydroxydopamine lesions was immediately reversed and the acute high rise of catecholamine serum level was significantly attenuated within 3 hours, accompanied by preserved cardiac output and decreased expressions of connexin 43 in the heart and lungs.	Hexamethonium	6-19	gap junction protein, alpha 1	Rattus norvegicus	301-312
25010841-7	2014	Furthermore, the decrease in ET-1 gene expression induced by re-feeding was blocked by pre-treatment with hexamethonium and atropine.	Hexamethonium	106-119	endothelin 1	Mus musculus	29-33
24504265-7	2014	This increase in rCBF was reduced significantly by the administration of hexamethonium and atropine.	Hexamethonium	73-86	CCAAT/enhancer binding protein zeta	Rattus norvegicus	17-21
22241831-8	2012	Effects of the highest dose studied were blocked by mecamylamine (general nAChR antagonist) and partially antagonized by hexamethonium (largely peripheral nAChR antagonist).	Hexamethonium	121-134	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	155-160
23149874-7	2012	Nicotinic acetylcholine receptor (nAChR) blocker hexamethonium, MEK1/2 inhibitor PD98059, p38 MAPK inhibitor SB203580 and NF-kappaB inhibitor PDTC almost completely abolished nicotineinduced CRP expression in mRNA and protein levels in U937 macrophages.	Hexamethonium	49-62	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	0-32
23149874-7	2012	Nicotinic acetylcholine receptor (nAChR) blocker hexamethonium, MEK1/2 inhibitor PD98059, p38 MAPK inhibitor SB203580 and NF-kappaB inhibitor PDTC almost completely abolished nicotineinduced CRP expression in mRNA and protein levels in U937 macrophages.	Hexamethonium	49-62	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	34-39
23149874-8	2012	The further study indicated that hexamethonium, PD98059, and SB203580 significantly inhibited ERK1/2 and p38 MAPK phosphorylation.	Hexamethonium	33-46	mitogen-activated protein kinase 3	Homo sapiens	94-100
23149874-8	2012	The further study indicated that hexamethonium, PD98059, and SB203580 significantly inhibited ERK1/2 and p38 MAPK phosphorylation.	Hexamethonium	33-46	mitogen-activated protein kinase 1	Homo sapiens	105-108
22635074-5	2012	In a second set of experiments, we demonstrated that the increased expression of myocardial phosphorylated-Akt and endothelial nitric oxide synthase induced by intrathecal morphine was blocked by prior administration of hexamethonium.	Hexamethonium	220-233	AKT serine/threonine kinase 1	Homo sapiens	107-110
22635074-5	2012	In a second set of experiments, we demonstrated that the increased expression of myocardial phosphorylated-Akt and endothelial nitric oxide synthase induced by intrathecal morphine was blocked by prior administration of hexamethonium.	Hexamethonium	220-233	nitric oxide synthase 3	Homo sapiens	115-148
22902499-5	2012	KEY FINDINGS: Both nAChR and mAChR antagonists (hexamethonium and methacine, respectively), per se, elevated histamine-releasing activity of the HMC-1 and suppressed the MC responses to most of investigated activators (carbachol, compound 48/80, and to a lesser extent aIgG).	Hexamethonium	48-61	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	19-24
21393361-7	2011	In addition, hexamethonium produced a greater decrease in blood pressure in Ang II-infused rats.	Hexamethonium	13-26	angiotensinogen	Rattus norvegicus	76-82
22127290-6	2012	This response was diminished reversibly by the non-selective nAChR blocker hexamethonium, by the selective alpha7 blocker alpha-bungarotoxin and by the alpha4-containing nAChR blocker erysodine.	Hexamethonium	75-88	cholinergic receptor nicotinic beta 1 subunit	Rattus norvegicus	61-66
22085992-10	2012	The nicotinic-acetylcholine receptor (nAChR) blocker hexamethonium induced a significant inhibition of the [(3)H]dopamine release produced by CC in PC12 cells but the TZ-elicited release of [(3)H]dopamine was 70% hexamethonium-insensitive, suggesting unidentified TZ toxins affecting other regulatory mechanisms of catecholamine secretion.	Hexamethonium	53-66	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	4-36
22085992-10	2012	The nicotinic-acetylcholine receptor (nAChR) blocker hexamethonium induced a significant inhibition of the [(3)H]dopamine release produced by CC in PC12 cells but the TZ-elicited release of [(3)H]dopamine was 70% hexamethonium-insensitive, suggesting unidentified TZ toxins affecting other regulatory mechanisms of catecholamine secretion.	Hexamethonium	53-66	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	38-43
22085992-10	2012	The nicotinic-acetylcholine receptor (nAChR) blocker hexamethonium induced a significant inhibition of the [(3)H]dopamine release produced by CC in PC12 cells but the TZ-elicited release of [(3)H]dopamine was 70% hexamethonium-insensitive, suggesting unidentified TZ toxins affecting other regulatory mechanisms of catecholamine secretion.	Hexamethonium	213-226	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	4-36
22085992-10	2012	The nicotinic-acetylcholine receptor (nAChR) blocker hexamethonium induced a significant inhibition of the [(3)H]dopamine release produced by CC in PC12 cells but the TZ-elicited release of [(3)H]dopamine was 70% hexamethonium-insensitive, suggesting unidentified TZ toxins affecting other regulatory mechanisms of catecholamine secretion.	Hexamethonium	213-226	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	38-43
22114134-6	2012	Additionally, the MVR response to hexamethonium was enhanced on days 10 and 13 of ANG II selectively in HS rats.	Hexamethonium	34-47	angiogenin	Rattus norvegicus	82-85
22114134-7	2012	Compared with LS rats, HR in HS rats was higher during the 2nd wk of ANG II, and its response to hexamethonium was greater on days 7, 10, and 13 of ANG II.	Hexamethonium	97-110	angiotensinogen	Rattus norvegicus	148-154
22029733-7	2011	The responses to suncus motilin in the stomach were completely abolished by atropine and tetrodotoxin treatment and significantly suppressed by administration of hexamethonium, verapamil, phentolamine, yohimbine, ondansetron, and naloxone, whereas ritanserin, prazosin, timolol, and FK888 did not affect the action of motilin.	Hexamethonium	162-175	motilin	Canis lupus familiaris	24-31